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Chapter 1
Abstract
In this chapter, we describe the fundamental aspects of the preparation of molecularly- 
defined scaffolds for soft tissue engineering, including the tissue response to the scaffolds 
after implantation. In particular, scaffolds prepared from insoluble type I collagen fibres, 
soluble type II collagen fibres, insoluble elastin fibres, glycosaminoglycans (GAGs) and 
growth factors are discussed. The general strategy is to prepare tailor-made "smart" 
biomaterials which will create a specific microenvironment thus enabling cells to generate 
new tissues. As an initial step, all biomolecules used were purified to homogeneity. Next, 
porous scaffolds were prepared using freezing and lyophilisation, and these scaffolds were 
crosslinked using carbodiimides. Crosslinking resulted in mechanically stronger scaffolds and 
allowed the covalent incorporation of GAGs. Scaffold characteristics were controlled to 
prepare tailor-made scaffolds by varying e.g. collagen to elastin ratio, freezing rate, degree 
of crosslinking, and GAGs attachment. The tissue response to scaffolds was evaluated 
following subcutaneous implantations in rats. Crosslinked scaffolds maintained their 
integrity and supported the formation on new extracellular matrix. Collagen-GAG scaffolds 
loaded with basic fibroblast growth factor significantly enhanced neovascularisation and 
tissue remodelling. Animal studies of two potential applications of these scaffolds were 
discussed in more detail, i.e. for bladder and cartilage regeneration.
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INTRODUCION
Tissue engineering is a rapidly growing area that aims to create, repair and/or replace 
tissues and organs by using combinations of biomaterials and cells. All tissues are composed 
of cells embedded in extracellular matrix. Tissue engineered constructs should have the 
capacity to become structurally integrated with the surrounding tissue, and to initiate 
restoration of essential functions of the lost or damaged tissue (1, 2). Most techniques of 
tissue engineering rely either on biocompatible scaffolds alone or a combination of scaffolds 
with cells to achieve new tissue formation. The scaffolds need to be compatible and 
designed to meet the nutritional and biological needs of the cell populations involved in the 
formation of new tissue (3). Ideally, scaffolds should be able to guide cells, which may be 
achieved by signals that sustain cellular growth, migration and differentiation (4). 
Engineered molecularly-defined smart scaffolds that resemble tissue-specific micro­
environments may provide a means to accomplish this goal.
Major extracellular matrix (ECM) components in tissue and organs are collagens, elastin, 
proteoglycans, laminin, fibronectin and glycosaminoglycans (GAGs). Each tissue has its own 
unique set and content of scaffold biomolecules (5). By selectively incorporating biologically 
active molecules into tissue-engineering constructs, cellular behaviour may be fine-tuned 
(6). Since scaffolds are to be used inside the human body, special demands are put upon 
preparations used for this purpose. These include: purity (to avoid immunological response 
due to contaminants), porosity (for cellular ingrowth), biocompatibility and biodegradability. 
In this study, scaffolds were constructed on basis of collagen and/or elastin, and combined 
with GAGs and growth factors. We will first focus on the properties of the individual 
components, next on the purification/production of these components, then on the 
preparation, characterisation and evaluation of porous matrices. Finally, we will discuss 
some potential applications for clinical use.
Collagen
Collagen provides strength and structural integrity to almost all organs in the body, 
especially skin, ligaments, cartilage, bone, tendon and dental elements (7-9). Fibrillar 
collagen is a 'triple helical' molecule (1.5 x 300 nm) with a molecular mass of about 300 kDa. 
It is composed of three left-handed polypeptides (a-chains) which are wrapped together to 
form a right-handed helical structure. The tight wrapping into a triple helix provides great 
tensile strength with virtually no capacity to stretch. Collagen molecules are grouped into 
fibrils in a head to tail alignment, and are covalently crosslinked to each other. At least 26 
genetically distinct types of collagen are known. Type I collagen is the main fibrillar collagen 
of bone, tendon, and skin and provides tissues with tensile strength. Insoluble type I collagen 
has found ample usage in the biomedical field (1, 4, 9-12). Type II collagen is the principal 
collagenous component of cartilage, intervertebral discs and the vitreous body. Its 
mechanical function is to provide tensile strength and resists shearing forces (13).
Elastin
Elastin provides elasticity to organs, especially skin, lung, arteries and ligaments (14). 
Elastin can stretch to several times its normal length. Despite its remarkable mechanical 
properties, elastin has found little use as a biomaterial (5, 15, 16). Elastin is a desirable 
protein for tissue engineering (15, 17). Due to its remarkable mechanical properties, 
elasticity and long term stability, elastin fibres maybe important in a wide variety of 
applications, including skin substitutes, vascular grafts, heart valves, and elastic cartilage.
9
Chapter 1
The high content of hydrophobic amino acids and intermolecular crosslinks (desmosine and 
isodesmosine) makes elastin one of the most chemically resistant proteins in the body. The 
precursor, tropoelastin, is composed of a 72 kDa single polypeptide chain. Individual 
molecules are secreted into the extracellular space, in association with microfibrillar 
components and crosslinked to each other to form elastic fibres (18).
Glycosaminoglycans (GAGs)
GAGs mediate many biological functions, e.g. hydration of tissue and the binding and 
modulation of effecter molecules such as growth factors and cytokines (19, 20). These 
characteristics are essential for basic cellular phenomena like cell adhesion, growth 
differentiation and activation, and implicate a role for GAGs in wound healing, inflammation, 
tissue morphogenesis and homeostasis. GAGs are linear polysaccharides compromised of 
alternating hexuronic acid and hexosamine residues (21). Due to the high degree of 
carboxylation and sulfation, GAGs are highly negatively charged molecules. Based on their 
backbone structure, GAGs can be grouped in four major classes; these are heparan sulphate 
(HS)/heparin, chondroitin sulfate (CS)/dermatan sulfate (DS), keratan sulfate (KS), and 
hyaluronic acid (HA). With the exception of HA, GAG chains are covalently attached to a core 
protein, forming proteoglycans. GAGs absorb water, causing osmotic swelling which 
provides the tissue with stiffness, strength and shock absorption (13). Characteristics like 
growth factor binding and biocompatibility can be exploited in biomaterials.
Growth factors
Growth factors are polypeptides that modulate cellular activities. Growth factors can 
either stimulate or inhibit cellular adhesion, migration, proliferation, and differentiation (22, 
23). Growth factors initiate their action by binding to specific receptors on target cells. 
Hundreds of growth factors have been identified, characterised and, based on structural 
homologies, grouped into at least twenty families and superfamilies (24). The ECM serves as 
a reservoir for growth factors, and promotes their long term bioavailability. Growth factors 
are stabilised and protected from proteolytic degradation by their interactions with e.g. 
GAGs. A sustained release of growth factors may be established by GAGs of ECM. HS for 
example, is a natural polysaccharide which stores and protects bFGF (25).
Specific control of tissue regeneration is achieved by controlled growth factor release 
from devices. Vascularisation of bioscaffolds is commonly a prerequisite for achieving 
appropriate tissue regeneration and function. Angiogenic factors like basic fibroblastic 
growth factors (bFGF) and vascular endothelial growth factor (VEGF) have a great potential 
for biomedical applications (26). bFGF stimulates the growth of smooth muscle cells and 
fibroblasts as well as endothelial cells, whereas VEGF primarily stimulates endothelial cells. 
Interestingly, combining VEGF and bFGF produces a greater and more rapid improvement in 
angiogenesis than administration of either VEGF or bFGF alone (27). bFGF is an 18 kDa 
protein with a length of 155 amino acids which does not contain disulfide bonds and is not 
glycosylated (28). VEGF is a 34- to 42-kDa heparin-binding dimeric ligand which appears in 
different isoforms (29). Since both growth factors have heparin binding sites, they can be 
specifically attached to GAG-containing scaffolds to improve neovascularisation and tissue 
generation.
The biocharacteristics of collagen, elastin, GAGs and growth factors make them valuable 
molecules to be incorporated into biomaterials. In the following, we will discuss the 
construction of tailor-made and biocompatible collagen-GAG and collagen-elastin-GAG 
scaffolds combined with growth factors, with defined physical, chemical, and biological
10
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characteristics, for use as a biomaterial for tissue engineering. Porous collagen or collagen­
elastin scaffolds were fabricated by freezing and subsequently lyophilisation of a suspension 
of highly purified collagen and elastin. GAGs were covalently attached by using carbodiimide 
crosslinking, thus offering the opportunities to exploit GAG-mediated phenomena such as 
binding, modulation, and release of growth factors, and allowing the construction of 
bioactive smart scaffolds (Fig. 1).
collagen-elastin scaffold
I ccosslinking ofscaffoid 
^  and attachment of GAG's
bioactive collagen-eiastin- 
glycosaminoglycan scaffold
Fig 1 Overview of the preparation of a bioactive scaffold: GAGs in blue and growth factors in green.
PREPARATION OF BIOACTIVE SCAFFOLDS
Isolation/production of components and purity assessment
Insoluble type I collagen was purified from bovine achilles tendon. Briefly, tendons were 
cleared from surrounding tissue, pulverised under liquid nitrogen conditions and extensively 
rinsed using diluted acetic acid, NaCl, urea, acetone and demineralised water as described 
(30). The purity and fibril structure of the type I collagen preparation was analysed by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), amino acid 
analysis, transmission electron microscope (TEM) and scanning electron microscope (SEM). 
SDS-PAGE indicated that the isolated collagen was essentially free of other proteins, and 
CNBr digestion of collagen revealed a specific type I collagen profile. TEM and SEM showed 
intact thin collagen fibrils with its characteristic striated pattern (Fig. 2A).
Soluble type II collagen was isolated from bovine tracheal cartilage. Trachea were 
defatted, stripped from surrounding conjunctiva, cut into small pieces (0.5 cm3) and 
washed/treated with Tris-HCl, guanidinium chloride, acetic acid, pepsin, and specific salt 
precipitation followed by dialysis against phosphate buffer (31). The purity of the type II 
collagen preparation was analysed by SDS-PAGE, amino acid analysis, and 
immunohistochemistry. No contaminating proteins could be detected by SDS-PAGE, and 
after CNBr digestion a profile typical for type II collagen was obtained. Amino acid 
composition revealed an increase in glycine, hydroxyproline and hydroxylysine residues, 
relative to tracheal cartilage. No chondroitin sulfate, a major component of cartilage, could 
be detected by immunohistochemistry.
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Insoluble elastin fibres were isolated from equine ligamentum nuchae. Non-elastinous 
tissue was removed and ligaments were pulverised and washed/treated with NaCl, organic 
solvents, CNBr in formic acid, urea with diluted 2-mercaptoethanol, and trypsin (32). The 
purity of the elastin preparation was analysed by SDS-PAGE, TEM and SEM. Only soluble 
contaminations and/or elastin breakdown products will enter an SDS-PAGE gel, whereas 
insoluble elastin will not. SDS-PAGE of the purified elastin indicated no contaminations. SEM 
and TEM indicated that the purified elastin fibres were intact and free of microfibrils and no 
other elements could be detected in contrast to traditionally prepared elastin (Fig. 2B) (33, 
34).
The GAGs chondroitin sulphate (CS) from bovine trachea and heparan sulphate (HS) from 
bovine kidney were isolated using extensive papain digestion, mild alkaline borohydride 
treatment, diethylaminoethyl (DEAE) ion exchange chromatography, and glycosidase 
digestion (35). Isolated GAGs were characterised by agarose gel electrophoresis (Fig. 2C) 
(36), and quantified using a modified Farndale-assay (37). To study whether protein 
contaminations were present, the GAG preparations were evaluated using SDS-PAGE under 
reducing conditions. According to these methods, no contaminations with other GAGs or 
proteins could be detected in CS and HS preparations.
The growth factors VEGF and bFGF (38) were produced in mg quantities using 
recombinant DNA technology and purified using immobilised heparin affinity 
chromatography. The purity and structure of these components are essential for the 
reproducible preparation of bioactive scaffolds. The purity and bioactivity of the growth 
factors were assessed using SDS-PAGE. The expressed and purified recombinant rat growth 
factors (VEGF and bFGF) had their apparent molecular weight and no contaminated proteins 
could be detected (Fig. 2D). Under non-reducing conditions, VEGF was present as a dimer, its 
active form. The biological activity of growth factors was evaluated in vitro using human 
umbilical vein endothelial cells for rrVEGF-164 and human dermal fibroblasts for rrbFGF (38). 
The addition of a growth factor stimulated cell proliferation threefold relative to cell cultures 
without growth factor.
Preparation of scaffolds
Scaffold morphology is another important aspect since it influences cellular migration and 
tissue remodelling. Cellular migration and supply of nutrients and oxygen is more 
straightforward when the scaffold has a higher porosity. To prepare a porous scaffold, 
collagen or collagen-elastin suspensions were made by incubation in diluted acetic acid at 
4oC for 16 h. The suspension was homogenised using a Potter-Elvehjem homogeniser, 
deaerated, poured into a mould, frozen and lyophilised, resulting in porous scaffolds. By 
using different freezing temperatures, the porosity of the collagen scaffold can be varied to 
some extent (39). With higher freezing rates, smaller ice crystals were formed, leading to a 
scaffold with a smaller average pore diameter.
12
General introduction & Aim of the study
Fig 2 Purity of scaffold components. Shown are: A) Type I collagen. SDS-PAGE of low molecular weight 
marker (LMW), purified type I collagen ai, a2 and ß chains, and bovine achilles tendon. Scanning and 
transmission electron microscopy showed intact collagen fibrils. B) Elastin. SDS-PAGE of low molecular 
weight marker (LMW), purified insoluble elastin, and equine ligamentum nuchae. After purification, no 
contaminants could be detected using SDS-PAGE, scanning and transmission electron microscopy. C) 
Chondroitin sulfate (CS) and heparan sulfate (HS). Agarose gel electrophoresis of GAG marker (CS, 
dermatan sulfate (DS) and HS) and isolated CS and HS. No other GAGs could be found. D) Vascular 
endothelial growth factor 164 (VEGF-164) and basic fibroblast growth factor (bFGF). No contaminants 
could be detected in VEGF-164 and bFGF with SDS-PAGE under non-reducing conditions. Bar is 10 ^m in 
SEM micrographs and 0.5 ^m in TEM micrographs.
To strengthen the porous structure and to covalently attach GAGs to the scaffold, 1-ethyl- 
3-(3-dimethyl aminopropyl) carbodiimide (EDC) crosslinking was used. EDC crosslinking is 
generally applied to prevent rapid degradation, to suppress antigenicity, and to improve 
mechanical properties. EDC is a zero length crosslinker which couples biomolecules to each 
other by virtue of an amide (peptide) linkage, which is non-toxic and biocompatible (40). The 
strength of the scaffold and the rate of biodegradation can be varied depending on the 
degree of crosslinking. The crosslinking of the scaffolds in the presence or absence of GAGs 
was performed using EDC and N-hydroxysuccinimide (NHS) in 2-morpholinoethane sulfonic 
acid (MES) in the presence of 40% ethanol for 4 h with or without HS or CS (5, 30). The 
presence of ethanol in the EDC solution preserves the porosity of the scaffold. Scaffolds 
were loaded with growth factors, by incubation in phosphate buffered saline (PBS) at 20oC, 
followed by incubation in PBS containing 7 |ag growth factor/ml for 1 h at 20oC, and washing 
with PBS to remove unbound growth factor.
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Characterisation of scaffolds
The morphology of the scaffold was characterised using SEM. The air-and pan-side of the 
scaffold consisted of porous structures with pore diameter ranging from 20 to 200 |am (Fig. 
3A). The inner site generally consisted of lattice like structures when scaffolds were frozen at 
-80°C. Collagen fibrils and elastin fibres physically interacted with each other in the collagen­
elastin scaffold. Collagen and elastin were randomly distributed in the scaffold, although 
elastin tended to be present in small clusters (Fig. 3B). EDC crosslinking and GAG coupling to 
the scaffolds did not alter the porosity (35).
Fig 3 Scanning electron micrographs of a porous scaffold made of A) 100% collagen and B) 50% collagen 
and 50% elastin. The small fibrils consist of collagen, and the large fibres are elastin (arrows). Bar is 10 
^m.
Physicochemical characteristics of various non-crosslinked and crosslinked collagen 
(elastin)scaffolds, with and without GAGs, are shown in Table 1. The degree of scaffold 
crosslinking was assessed by determination of the amine group content of the scaffolds 
spectrophotometrically after using 2,4,6-trinitrobenzene sulfonic acid (40). The rate of 
crosslinking depended on the amine group content of the non-crosslinked scaffold and the 
crosslinking conditions. The amine group content of collagen is higher than elastin, thus 
more crosslinks could be induced in collagen scaffolds than collagen-elastin scaffolds (5). Up 
to 60% of the available amine groups were used in the crosslinking reaction (5, 30, 35). For 
collagenous scaffolds, the denaturation time Td is also indicative for the degree of 
crosslinking. The Td of collagen scaffolds was determined by differential scanning calorimetry 
and could be increased from 62 to almost 80°C by crosslinking (30).
The amount of GAGs was determined by hexosamine analyses using p-dimethyl- 
aminobenzaldehyde (41). The GAG amount bound to the scaffold depended on the rate of 
crosslinking and the type of GAG. Up to 10% of HS and 6% of CS could be incorporated in the 
scaffolds. Specific phage display-generated antibodies (42) were used to localise these GAGs 
in the scaffold (43). Immunostaining indicated that the covalently bound GAGs were 
distributed throughout the whole scaffold (Fig. 4) (5).
The total amount of bFGF bound to the scaffold and its release were determined using 
radioactive labelling with 125I. Crosslinked scaffolds, with and without HS, revealed a biphasic 
release profile, i.e. an initial burst of bFGF followed by a gradual and sustained release. More 
bFGF could be bound to a HS-containing scaffold (1.26% vs. 0.37%) compared to a scaffold 
without GAG (38). Immunohistochemistry was also used to localise growth factors in the 
scaffold, and bFGF was mainly localised at the margins of the scaffold (38).
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Table 1. Biochemical, biophysical and biomechanical characteristics of various scaffolds.
Scaffold Crosslinked Denaturation Amine group Amount of Amount of Water-binding Tensile strength E-modulus
with EDC/NHS Temperature content GAG per g bFGF per g capacity [kPa] [MPa]
Td [°C] [nmol/g] scaffold [mg] scaffold [Mg] [# times dry weight]
COL - 62 ± 1 281 ± 7 0 0 20 ± 1 103 ± 15 0.39 ± 0.07
COL + 79 ± 1 185 ± 3 0 0 20 ± 1 677 ± 191 1.03 ± 0.08
COL-CS + 77 ± 1 186 ± 8 100 ± 4 0 33 ± 3 520 ± 105 0.97 ± 0.07
COL-EL 1:1 - N.D. 147 ± 12 0 0 16 ± 1 63 ± 23 0.24 ± 0.06
COL-EL 1:1 + N.D. 87 ± 5 0 0 16 ± 3 142 ± 8 0.42 ± 0.04
COL-EL-CS 1:1 + N.D. 83 ± 2 58 ± 5 0 21 ± 3 128 ± 10 0.54 ± 0.11
COL + 72 ± 1 236 ± 9 0 0 N.D. N.D. N.D.
COL-bFGF + 72 ± 1 236 ± 9 0 372 ± 75 N.D. N.D. N.D.
COL-HS + 69 ± 1 227± 17 60 ± 5 0 N.D. N.D. N.D.
COL-HS-bFGF + 69 ± 1 227± 17 60 ± 5 1260 ± 207 N.D. N.D. N.D.
COL= collagen; EL= elastin; CS= chondroitin sulfate; HS= heparan sulfate; bFGF= basic fibroblast growth 
factor. Scaffolds above the dashed line were crosslinked with 33 mM EDC and 6 mM NHS; scaffolds 
below with 14 mM EDC and 8 mM NHS. Results are mean + SD of at least 3 individual experiments. 
Values from (5, 38).
type I collagen elastin CS
CO L-CS
COL-EL{9:1)-CS
COL-El{1:1)-CS
COL-EL(1:9)-CS
Fig 4 I mmunostaining of scaffolds containing variable amounts of collagen and elastin with covalently 
attached chondroitin sulfate using immunostaining for type I collagen (red) and CS (green), whereas 
elastin was analysed by UV optics (blue). Bar is 50 ^m. COL=collagen, EL=elastin, CS=chondroitin 
sulphate. Figure modified with permission from Daamen etal. (5).
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TISSUE RESPONSE TO COLLAGENOUS SCAFFOLDS (38, 43)
Before a bioactive scaffold can be applied for tissue engineering, the tissue response and 
biocompatibility have to be studied in animal models. To evaluate the tissue response, 
collagenous scaffolds were implanted subcutaneously in 3 months old male Albino Oxford 
rats for periods up to 10 weeks. On the back of the anaesthetised rats, subcutaneous 
pockets were made and scaffolds (0 8 mm) were implanted at a distance of about 1 cm from 
the incisions. The implants with surrounded tissue were harvested at day 2, and at 1, 2, 4, 
and 10 weeks after implantation. The tissue response was evaluated by using 
(immuno)histological methods. Results were analysed for non-crosslinked and crosslinked 
scaffolds with and without GAGs and with and without growth factors.
Collagen Collagen + HS
Fig 5 Light-microscopy of subcutaneously implanted crosslinked collagen scaffolds. Shown are: A) 
collagen and B) collagen-HS scaffold immunostained for type IV collagen as a marker for blood vessels 2 
weeks after implantation. Note that HS induces angiogenesis. c= capsule surrounding the implants; s= 
implanted scaffold. C) collagen-bFGF and D) collagen-HS-bFGF scaffold 10 weeks after implantation (HE 
staining). Arrows indicate blood vessels. Bar indicates 25 ^m in (A, B) and 50 ^m in (C, D). Figure A and B 
reproduced from Pieper et al. with permission (43).
Non-crosslinked collagen scaffolds were gradually resorbed and completely replaced by 
collagenous connective tissue 10 weeks after implantation. Crosslinked collagen scaffolds, 
however, maintained their integrity for at least 3 months and supported the formation of 
new ECM, i.e. deposition of type I and III collagen.
To study the effect of GAGs (e.g. HS and CS), crosslinked collagen scaffolds with and 
without GAGs were implanted. Even after 10 weeks, the GAGs remained immobilised on the 
collagen scaffold as analysed by immunohistochemistry. An increased angiogenesis was 
found in collagen-HS relative to collagen scaffolds (Fig. 5A and B), indicating the angiogenesis
16
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promoting activity of HS. The presence of GAGs preserved the porous scaffold structures and 
delayed scaffold degradation. After 10 weeks of implantation, a minor infiltration of 
macrophages and giants cells was observed in both collagen-HS and collagen-CS scaffolds. It 
was therefore concluded that attachment of GAGs to collagenous scaffolds modulated tissue 
response.
The presence of GAGs promoted angiogenesis into the scaffold periphery. Angiogenesis 
could be further enhanced by loading the collagen-HS scaffold with bFGF. A number of 
growth factors, including bFGF, have a high affinity for HS and display angiogenic and 
mitogenic properties. Binding bFGF to collagen-HS scaffolds resulted in a major influx of 
cells. Collagen-HS-bFGF scaffolds became highly vascularised and remained their structural 
integrity throughout the implantation period (Fig. 5C and D). Although bFGF distribution was 
not homogenous, vascularisation was increased throughout the scaffold after subcutaneous 
implantation. bFGF loading of crosslinked collagen-GAG scaffolds is thus of additional value 
for tissue engineering applications that require angiogenesis.
SOME APPLICATIONS
Collagen scaffolds for bladder augmentation (rabbit) (44)
Approximately 1.2 million people worldwide suffer from bladder disease. Individuals with 
end-stage bladder disease often require bladder replacement or repair (45). Currently, most 
common techniques of bladder reconstruction with intestinal tissues are associated with 
various complications like mucus productions, chronic bacteria, stone formation, leakage 
and ruptures, electrolyte imbalance and possible development of malignancies (46-48). 
Different biodegradable scaffolds have been used for pre-clinical studies. Among these, SIS is 
a xenogenic membrane that is harvested from porcine small intestine, which is mainly 
composed of a submucosal layer (49). Complications occur when using grafts for bladder 
reconstruction, i.e. graft shrinkage, graft incrustation, or infection (45, 50-54). A collagen- 
based biocompatible and biodegradable scaffold may solve these problems.
The operation procedure was as follows: the bladder of a New Zealand white rabbit (2.5­
3.5 kg) was exposed and part of the ventral surface of the detrusor (1.5 x 1.5 cm) resected 
(Fig. 6A). Collagen scaffolds were sewed into place with a running resolvable suture (6 x 0 
Monocryl, Ethicon, USA) and four non-resolvable marker sutures (Fig. 6B). The bladder was 
then filled with saline solution to examine leakages (Fig. 6C). None of the scaffolds showed 
any leakage. After 1 month, the urothelium on the scaffold was multilayered and some 
ingrowth of smooth muscle cells was observed (Fig. 6E). After three months, the scaffold was 
fully incorporated in the bladder tissue (Fig. 6D) and after 9 months, the central smooth 
muscle cells and the periphery of the graft were further organised and the muscle layers 
were in a similar direction as the native bladder muscle layer (Fig. 6F). The collagen scaffold 
showed good epithelialisation and ingrowth of smooth muscle cells. However, a few rabbits 
developed bladder stones. A considerable amount of rabbits showed encrustation (adhesion 
of urate/CaOx microcrystals) after 2 weeks, but these remarkably disappeared in time (3-9 
months). Future research focuses on the introduction of HS and epidermal growth factor 
(EGF) on to the scaffolds in order to improve the regeneration of the bladder wall.
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Fig 6 Surgery and immunohistochemistry of an augmentation cystoplasty using a crosslinked type I 
collagen scaffold. Shown are: A) exposed bladder; B) collagen scaffold being sewed into the resected 
bladder; C) bladder with collagen scaffold filled with saline solution to examine leakage; D) collagen 
scaffold 3 months after implantation incorporated in the bladder wall; E) immunostaining of urothelium 
with cytokeratin 5 and 8 one month post-operatively; F) Masson trichrome staining of bladder wall with 
collagen scaffold three months post-operatively (arrows indicate muscle cells). Figure reproduced with 
permission from Elsevier (44).
Tissue engineering of cartilage (55)
The extracellular matrix of articular cartilage consists mainly of type II collagen and 
glycosaminoglycans (GAGs). The collagen of articular cartilage is organised in a highly specific 
way. Most collagen bundles run from the deep mineralised layer of the cartilage to the 
superficial zone of the cartilage where they bent to run parallel to the surface. The cells of 
articular cartilage, the chondrocytes, lie more of less scattered in this matrix. In the 
superficial region, they are parallel to the surface, in the deeper regions they are located in 
columns perpendicular to the surface in-between the collagen bundles. The tissue is not 
innervated by nerves and is avascular, making spontaneous repair after injury or disease 
slow. With the increase in frequency of osteoarthritis and cartilage trauma in the population, 
makes cartilage a particular target for tissue engineering (56). Various scaffolds have been 
reported for tissue engineering of cartilage (31, 57-61).
An initial in vivo experiment was performed to evaluate the effect of collagenous 
scaffolds for cartilage regeneration. Scaffolds, made from isolated and crosslinked type I and
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II collagen with and without attached chondroitin sulphate (CS), were tested on their 
cartilage inductive properties in knees of young rabbits. Scaffolds were implanted into full­
thickness articular cartilage defects. After luxation of the patella, two full-thickness defects 
(0 4 mm; 3 mm high) were made in the trochlea (Fig. 7A). Type I and II collagen scaffolds 
(Fig. 7B), with or without CS, were implanted and empty defects were used as controls (Fig. 
7C). The follow-up period was 4 and 12 weeks. Empty control defects showed a considerable 
healing response consisting of the restoration of the original cartilage contours with 
cartilaginous-like tissue, and in the 12-week group, remodelling of the deeper area of the 
defect into bone. This unexpected good repair of the empty defects was probably related to 
the relatively young rabbits, which are known for their larger repair potency compared to 
older animals. Although differences between different scaffold types was not very large, 
type I and II collagen scaffolds in combination with CS showed a trend for a better defect 
repair as compared to the same scaffolds without CS. Scaffolds were almost completely 
degraded after 12 weeks and integration with the subchondral bone and adjacent cartilage 
was observed. In some cases, a direct connection between the graft and host cartilage was 
found (Fig. 7D). Scaffolds based on both type I and II collagen appeared to be biocompatible 
and biodegradable and these scaffolds favoured the maintenance of the chondrocytic 
phenotype in the reconstructed defect area.
Fig 7 Surgery and histology of full-thickness/subchondrial defects in the rabbit knee joint. A) Two full 
thickness defects were created in the trochlea using a dental high speed drill into the subchondral bone. 
B) Wetted collagen scaffold to be placed in the defect. C) A type II collagen-CS scaffold is applied to one 
defect (left); an empty defect is used as a control (right). D) Light microscopy of a defect with implanted 
crosslinked type II collagen-CS scaffold 12 weeks after implantation showed that the cartilage-like tissue 
of the implant site (right of arrowhead) is in some cases directly connected to the adjacent host tissue 
(left of arrowhead). Figure D reproduced from Buma et al. with permission from Elsevier (55).
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AIM OF THIS THESIS
The primary aim of this study was to develop novel tissue engineering tools for clinical 
applications. Tissue engineering and regenerative medicine are fairly new disciplines which 
aim on the regeneration of damaged or lost tissues. One of the basic principles of tissue 
engineering is the use of biocompatible materials which restore local processes. Within 
regenerative medicine, various approaches are known, e.g. the use of scaffolds, injectables, 
coatings and/or delivery devices. The development and applicability of novel tissue 
engineering tools is the main aim of this thesis.
A review about the fundamental aspects of the preparation of molecularly-defined 
scaffolds for soft tissue engineering is presented in chapter 1. Particularly the preparation of 
scaffolds composed of type I collagen, elastin, glycosaminoglycans and growth factors, and 
the possible applications are discussed. In chapter 2, the large production and purification of 
a vascular endothelial growth factor (VEGF) using the Pichia pastoris expression system is 
demonstrated. This growth factor plays a key role in the enhancement of local angiogenesis, 
which will be further addressed in chapter 3. In this chapter, the preparation and sub­
cutaneous implantation of collagen-glycosaminoglycan scaffolds with VEGF and/or FGF-2 is 
presented, highlighting the neovascularisation and tissue response.
Collagen is well known for its adjunct for hemostasis. When collagen comes in contact 
with blood, the primary hemostasis is initiated. This makes collagen a good candidate for 
local hemostasis, e.g. pseudoaneurysms treatment. In chapter 4, a new pig model for 
femoral pseudoaneurysm is described. This model is used in Chapter 5 which addresses the 
preparation and characterisation of injectable collagen, and its use for femoral arterial pseu­
doaneurysm treatment.
Chapter 6 and 7 describe straightforward methods to prepare micro-capsules (lyo- 
philisomes) and injectable micro-scaffolds, and discuss the possibilities and further strategies 
for their use in both drug delivery and tissue engineering.
Finally, summary and future directions are given in chapter 8.
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ABSTRACT
INTRODUCTION Large-scale production of recombinant rat vascular endothelial growth 
factor (rrVEGF-164) is desirable for angiogenic studies. METHODS In this study, biologically 
active recombinant rat vascular endothelial growth factor (rrVEGF-164) was cloned and 
expressed in the yeast P. pastoris, and large-scale production was performed by fer­
mentation. cDNA encoding VEGF-164 was prepared from embryonic rat tissue RNA, and a 
recombinant pPIC9HV/rVEGF-164 plasmid, containing an AOX1 promoter, was constructed. 
The methylotrophic P. pastoris was used as the eukaryotic expression system. RESULTS After 
transformation, rrVEGF-164 was produced by fermentation (~124 mg/L) and purified by 
heparin affinity chromatography. SDS-PAGE indicated that rrVEGF-164 was produced as a 
disulphide-bridged dimer of 48 kDa which was purified to near homogeneity by heparin 
affinity chromatography in a large quantity. A bioassay indicated a three to five-fold increase 
in endothelial cell proliferation after 3 days, due to the addition of the produced rrVEGF-164. 
The produced rrVEGF-164 showed a higher biological activity than a commercially available, 
mouse cell line-based, growth factor. CONCLUSIONS In conclusion, using the P. pastoris 
expression system we were able to produce biologically active rat VEGF-164 in high 
quantities and this may provide a powerful tool for basic and applied life sciences.
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INTRODUCTION
Vascular endothelial growth factor (VEGF) is one of the most celebrated mediators in the 
process of angiogenesis. VEGF is a hypoxia-inducible protein that promotes the proliferation 
and survival of vascular endothelial cells (1). At least five different rat VEGF alternatively 
spliced isoforms have been identified originating from a single VEGF pre-mRNA: VEGF-120, - 
144, -164, -188 and -205 (2-4). These isoforms resemble the human VEGF isoforms (VEGF- 
121, -145, -165, -189 and -206) and differ in length from them by one amino acid. VEGF is 
only active in its dimeric form (5, 6). All rat VEGF isoforms are mitogenic to vascular endothe­
lial cells and induce permeabilisation of blood vessels (7). VEGF-164, VEGF-188 and VEGF- 
205 are able to bind heparin (7-9). VEGF-164 binds to the VEGF receptor (VEGFR) present on 
endothelial cells, stimulating the production of matrix metalloproteinases (MMPs). MMPs 
degrade the basement membrane, allowing proliferation and migration of endothelial cells 
towards the interstitium, so-called sprouting. Subsequently, pericytes proliferate and 
migrate towards the newly formed sprouts and induce maturation by forming a layer around 
the sprout (10, 11).
Large-scale production and purification of rat VEGF-164 is desirable for angiogenic studies 
in vitro and in vivo, especially in rat animal models for tissue engineering in which enhanced 
angiogenesis is an issue. Since the source of natural (rat) growth factors is limited, attempts 
have been made to produce growth factors on a large-scale by recombinant DNA 
technology. Growth factors have been produced in Escherichia coli and have played an 
important role in basic research of rat angiogenesis (12, 13). E. coli is a prokaryote and its 
intrinsic characteristics such as protein processing, protein folding, and post translational 
modi-fications, differ from those of eukaryotes. In E. coli, dimeric growth factors such as 
VEGF are produced as a monomer and need to be dimerised after production. The Pichia 
pastoris yeast expression system allows correct folding of dimeric proteins in addition to 
efficient expression, intact secretion, large-scale production, and stable genetics (14, 15). 
Human VEGF has been efficiently expressed in P. pastoris (16). Expression of biologically 
active rat VEGF in P. pastoris, however, has -to our knowledge- never been published.
In this study, rrVEGF-164 was inserted into the pPIC9HV expression vector and 
transfected into the P. pastoris yeast cells. RrVEGF-164 was secreted in large quantities, 
purified using heparin affinity chromatography, and it's biological activity was studied in 
vitro using human umbilical vein endothelial cells (HUVECs).
MATERIALS AND METHODS
Materials
Unless stated otherwise, all materials were from Merck (Darmstadt, Germany). The VEGF 
upstream (5'-GTA GAA TTC GCA CCC ACG ACA GAA GG-3') and VEGF downstream (5'-TAT 
GCG GCC GCT CAC CGC CTT GGC TTG T-3') primer containing EcoRI and NotI restriction sites 
were synthesised by Isogen Biosciences BV (Maarssen, The Netherlands). The P. pastoris 
expression vector pPIC9 and P. pastoris host strain GS115 were purchased from Invitrogen 
Corp. (Carlsbad, CA, USA). The commercial rrVEGF-164, produced in a mouse myeloma cell 
line (R&D Systems, Minneapolis, MN, USA) was used as a positive control and for reference.
LB-medium consisted per litre of; 10 g NaCl, 10 g peptone (Gibco BRL), 5 g yeast extract 
(Difco Laboratories, Detroit, MI, USA), containing 10 g glucose and 0.1 g ampicillin (Sigma).
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Buffered Glycerol-complex Medium (BMGY) containing glycerol as the carbon source, 
consisted per litre of; 10 g yeast extract, 20 g peptone, 21.2 g potassium sulphate (pH 6.0), 
13.4 g yeast nitrogen base (YNB) (Sigma Chemical Co., St Louis, MO, USA), 0.4 mg biotin and 
10 ml glycerol.
Buffered Methanol-complex Medium (BMMY) is similar to BMGY, but with 5 ml methanol 
instead of glycerol.
Basal salts medium (BSM) consisted per litre of; 26.7 ml phosphoric acid, 1.18 g calcium 
sulphate-2H2O, 18.2 g potassium sulphate, 14.9 g magnesium sulphate-7H2O, 4.1 g 
potassium hydroxide and 40 ml glycerol.
PTM1 trace salts (Invitrogen) consisted per litre of; 5 ml sulphuric acid, 6 g cupric 
sulphate-5H2O, 0.08 g sodium iodide, 3 g manganese sulphate-H2O, 0.2 g sodium 
molybdate-2H2O, 0.02 g boric acid, 0.5 g cobalt chloride, 20 g zinc chloride, 65 g ferrous 
sulphate-7H2O, and 0.2 g biotin.
YPD-medium consisted per litre of; 10 g yeast extract, 20 g peptone, 20 g D-glucose, with 
100000 U penicillin and 0.1 g streptomycin (Gibco BRL).
YNB dropout plates consisted per litre of; 6.7 g YNB, 1.92 g yeast synthetic dropout medium 
supplement (Sigma), 20 g glucose and 20 g agar (Gibco BRL).
TYE agar plates consisted per litre of; 8 g NaCl, 10 g peptone, 5 g yeast extract, 15 g agar 
(Gibco BRL), 10 g glucose and 100 g ampicillin (Sigma).
Preparation of rat VEGF-164 cDNA
Total RNA was isolated from Rattus norvegicus embryonic tissue (17 days post­
conception) using the SV Total RNA Isolation System (Promega, Madison, WI, USA). After 
denaturation (10 min at 65°C) of the total RNA (~0.5 |ag), cDNA (~0.4 |ag) was synthesised 
using hexanucleotide primers. A reverse transcriptase reaction was performed for 90 min at 
37°C using the following reaction mixture; 200 units reverse transcriptase (Promega) in 50 
mM Tris-HCl (pH 8.3) containing 75 mM KCl, 3 mM MgCl2 [M-MLV Reversed Transcriptase 
buffer (Gibco BRL, Gaithersburg, MD, USA)], 1 mM deoxynucleoside triphosphates (dNTPs) 
and 10 mM DTT (Gibco BRL) in a total volume of 20 |l. PCR fragments of the full-length cDNA 
were prepared with 10 mM Tris-HCl (pH 8.3) containing 50 mM KCl, 1.5 mM MgCl2, 100 |M 
dNTPs, 20 |M rrVEGF-164 primers and 1 unit Taq polymerase (Promega) in a total volume of 
50 |aL. The PCR was performed on a Peltier Thermal Cycler (PTC-200; MJ Research and 
Biozym, Landgraaf, The Netherlands), with a 30 cycles program (95°C for 60s, 65°C for 60s, 
72°C for 90s and extension at 72°C for 5 min). The rrVEGF-164 cDNA was isolated from a 2% 
(w/v) agarose gel and purified with a QIAEX II gel extraction system (QIAGEN, Hilden, 
Germany). The SMART-ladder marker (Eurogentec) was used to estimate the sizes of the PCR 
products.
Construction of expression vector
The purified cDNA was subcloned into the vector pPIC9HV (J.M.H. Raats, Dept. of Bio­
chemical Chemistry, Radboud University Nijmegen Medical Centre, Nijmegen, The 
Netherlands, unpublished data (pPIC9 expression plasmid was obtained from Invitrogen)) 
after digestion with EcoRI and NotI (Invitrogen) in the presence of 1x React® 3 buffer 
(GibcoBRL) for 1 h at 37°C. The pPIC9HV is similar to the original pPIC9 vector (17, 18), but 
contains a polyhistidine and VSV-tag for detection and purification. The rrVEGF-164 insert 
was ligated into pPIC9HV vector DNA using T4 ligase (Gibco BRL) in T4 ligase buffer (Gibco 
BRL) for 24 h at 16°C.
The host strain Escherichia coli (supE44AlacU169 ($80lacZAM15) hsdR17 recAl endAl 
gyrA96 thi-1 relA1) was transformed with the expression vector by heat-shock (45 s at 42°C).
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The E. coli cells were incubated for 1 h at 37°C in LB-medium. After 1 min of centrifugation at 
14000g, the transformed E. coli cells were applied to a TYE agar plates and incubated for 24 
h at 37°C. The rrVEGF-164 positive transformants were selected by means of ampicillin anti­
biotic resistance due to the presence of ampicillin resistance gene (AMP) in the Pichia ex­
pression vector. Ampicillin resistant E. coli transformants were selected and suspended in 
LB-medium. After 24 h incubation at 37°C at 200 rpm in an orbital shaker, the suspension 
was centrifuged for 1 min at 14000g. Plasmid DNA was isolated using the QIAprep spin mini- 
prep kit (QIAGEN) according to the manufacturer's instructions, and positive transformants 
were identified by automated sequencing using an a-factor primer (5'- 
ACTACTATTGCCAGCATTGCTGCT-3') at the DNA Sequencing Facility, Dept. of Human 
Genetics, Radboud University Nijmegen Medical Centre, The Netherlands.
Transformation into P. pastoris yeast cells
P. pastoris GS115 cells were grown in 100 ml YPD-medium overnight at 30°C at 200 rpm 
in an orbital shaker, until an OD600 of 1.5 was reached, which corresponds to a cell density 
of approximately 109 cells/ml. Competent GS115 cells were freshly prepared before trans­
formation by consecutive washings with ice-cold sterile MilliQ water and 1 M sorbitol 
according to the Invitrogen manual. The DNA was linearised by digesting 10 |g of plasmid 
DNA with SalI. Subsequently, the linearised DNA was purified using the QIAGEN PCR cleanup 
kit. To clone the expression vector into the P. pastoris yeast cells, cells were resuspended in 
1 M sorbitol on ice, and 80 |l of competent cells were electroporated by means of pulse 
discharges (1.5 kV, 25 |F, 400 Ohm, Bio-Rad Gene Pulser, CA, USA) for 9 ms in the presence 
of 10 |g linearised plasmid DNA (20 |l). After electroporation, cells were put on ice for 5 
min, 10x diluted in 1 M sorbitol and incubated for 1 h at 30°C (without shaking). Cells were 
spread on YNB dropout plates and incubated at 30°C. The plasmid contains the His4 gene 
(encoding histidinol dehydrogenase) which initiates the yeast cell to synthesise histidine 
(His+). Therefore, only positive transformants can grow on the histidine deficient plates (YNB 
dropout plates), which can be used for positive clone selection (19). After 2 days of culturing, 
the positive transformants were counted, picked, and streaked on new dropout plates. After 
a 45 h incubation at 30°C, single colonies were picked and cultured in a baffled flask contain­
ing 25 ml BMGY-medium for an overnight period at 30°C at 200 rpm in an orbital shaker. To 
store the cultures, frozen stocks were prepared by adding 60% (v/v) glycerol (0.5 ml) to the 
P. pastoris recombinants in YPD-medium (0.5 ml) and freezing at -80°C.
Expression screening of rrVEGF-164
To analyse the expression levels of the constructed transformants, a small-scale 
expression screening was performed using a fast induction method with methanol. His+ 
trans-formants were picked and added to 15 ml BMGY-medium, and cultured in 200 ml baf­
fled flasks overnight at 30°C, 200 rpm in an orbital shaker. To induce production of rrVEGF- 
164, cells were centrifuged (1500g, 4°C, for 10 min) and resuspended in BMMY-medium con­
taining 25% (v/v) methanol as the major carbon source. Cells were incubated for 2 days at 
30°C, 200 rpm in an orbital shaker. After centrifugation (1500g, 4°C, 10 min), the secreted 
rrVEGF-164 was concentrated from the supernatant by adding 50 |l heparin-acryl beads 
(Sigma Chemical Co.) to 1 ml supernatant, and incubation for 1 h at 21°C under rotating con­
ditions. Heparin beads were concentrated by centrifugation (1500g, 4°C, 10 min) and 
analysed using SDS-PAGE and Western blotting analysis as described below.
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Large-scale production of rrVEGF-164
For large-scale rrVEGF-164 production, a 1 L baffled flask with 200 ml YNB-medium was 
inoculated with 1 ml thawed P. pastoris host strain GS115 containing the rrVEGF-164 
expression vector. An overnight culture was incubated at 30°C at 200 rpm in an orbital 
shaker until an OD600 of approximately 6 was reached. The Bioflo® 3000 fermentor (New 
Brunswick Scientific, Edison, NJ, USA), containing 2 L of basal salts medium, was sterilised by 
autoclaving for 45 min at 121°C. After autoclaving, 4.35 ml/L PTM1 trace salts (Sigma) were 
added aseptically to the initial fermentation volume. Ammonium hydroxide (28% (w/v), 
Sigma) was used as a nitrogen source and to increase the pH during the fermentation 
process. The 200 ml inoculum was transferred into the fermentor after setting the dissolved 
oxygen (DO) at 100%, the pH at 6.0 and the temperature at 30°C. Anti-foam solution 289 
(Sigma) diluted 1:500 in MilliQ water was used to reduce foam production during fer­
mentation. Yeast cells use oxygen for oxidative metabolism of glycerol. When glycerol is con­
sumed the need for oxygen declines and as a consequence the DO rises. After approximately 
24 h of batch culture, the glycerol was completely consumed which was indicated by a sharp 
rise in DO (up to 70%, see Fig. 4). The 5 h glycerol fed-batch was started by feeding 50% (v/v) 
glycerol con-taining 12 ml/L PTM1 trace salts with feed rate of 18.15 ml/L/h. After the 
glycerol was used (DO of ~100%), the methanol feed (100% (v/v) methanol (Labscan) with 12 
ml/L PTM1 trace salts) was started to fully induce the AOX1 promoter of the expression 
system. During the methanol feed, DO decreased rapidly from ~100% to 30% and was 
continued at 30% for another 30 h. The culture was then harvested and centrifuged (20 min 
at 5000 g). The supernatant was filtered using a 0.45 |m cellulose acetate membrane filter 
(Schleicher and Schuell, Dassel, Germany) and dialysed against 10 mM phosphate buffered 
saline (pH 7.4).
Purification and identification of rrVEGF-164
For purification of rrVEGF-164, the dialysed supernatant (300 ml) was 1:1 diluted with 10 
mM phosphate buffer (PB) containing 0.2 M NaCl and adjusted to pH 7.0 with 1 M Na2HPO4. 
The solution was subjected to fast protein liquid chromatography (FPLC), using a 5 ml 
heparin-sepharose HiTrap™ column (Amersham Biosciences, Stockholm, Sweden). The 
rrVEGF-164 was eluted with 1 M NaCl in 10 mM PB (pH 7.0) for 20 min, followed by 2 M NaCl 
in 10 mM PB (pH 7.0) for 20 min at 2.5 ml/min for both solutions (see Fig. 5). Five fractions 
(2.5 ml/fraction) with highest A280 absorbance were collected, pooled and directly frozen at 
-80°C. Purity and dimer formation were evaluated by sodium dodecyl sulphate poly­
acrylamide gel electrophoresis (SDS-PAGE; 15% (w/v); Serva GmbH, Frankfurt, Germany) 
(20). Briefly, the supernatant was diluted 1:1 with sample buffer with and without 5% (v/v) 
P-mercaptoethanol (with and without reducing conditions) and denatured for 5 min at 95°C. 
Then 10 |l (~0.6 |g) of denatured rrVEGF-164 was loaded on the gel and was visualised by 
Coomassie Brilliant Blue (0.1% (w/v)) staining or further identified by Western blotting using 
goat anti-rat VEGF antibody (1:1000) (R&D Systems) (21). The amount of purified rrVEGF-164 
was determined by a Lowry analysis using bovine serum albumin (BSA) as a standard (22).
Biological activity of produced rrVEGF-164
Human umbilical vein endothelial cells (HUVECs, ATCC, CRL-1730, Rockville, MD, USA) 
were grown in F12K medium (Gibco BRL, Carlsbad, CA, USA) with 20% (v/v) foetal calf serum 
(FCS), 1.5 % (w/v) calf brain extract (as a source for endothelial cell growth factor (ECGF)), 
0.14 mg/ml heparin, 200 mM L-glutamine, 100 U/ml penicillin and 100 |g/ml streptomycin 
(Gibco BRL). After coating the 96-wells plate with 1% (v/v) gelatine, 4000 cells were seeded 
per well and these were left to attach overnight in the above medium without ECGF. Next,
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medium was replaced by F12K medium without ECGF and 0-100 ng/ml rrVEGF-164 was 
added. A cell proliferation assay (WST-1, Roche, Mannheim Germany), based on the 
reduction of a tetrazolium salt to formazan by mitochondrial dehydrogenases in viable cells, 
was used to determine the relative number of cells at day 1 and 3 (23). Proliferation of cells 
in medium without VEGF was set to 100%. A student's t-test was used for statistical analyses 
and p<0.05 was considered statistically significant.
RESULTS AND DISCUSSION
Preparation of rat VEGF-164 cDNA
Total RNA was isolated from embryonic Rattus norvegicus tissue and transcribed into 
cDNA using random hexanucleotide primers. After amplification with VEGF specific primers, 
PCR products were separated on agarose gel, and three VEGF splice variants (VEGF-188 
(564bp), VEGF-164 (492bp) and VEGF-120 (360bp)) could be identified on the basis of their 
molecular mass (Fig. 1A). The 492bp fragment was extracted from the gel, and reamplified. 
This fragment and the pPIC9HV vector were cut with EcoRI and NotI and put on an agarose 
gel for isolation and for further ligation (Fig. 1B).
Fig 1 Aga rose gel electrophoresis of PCR products. A) ethidium bromide-stained agarose gel shows in 
lane 1: DNA marker, lane 2: PCR products after amplification using VEGF specific primers, indicating 
three VEGF splice variants, VEGF-188 (564bp), VEGF-164 (492bp) and VEGF-120 (360bp). B) lane 1: DNA 
marker, lane 2: the rrVEGF-164 insert (492 bp) and in lane 3 the pPIC9HV vector (8580 bp).
Construction of expression vector
After EcoRI and NotI digestion, purification and ligation, the resulting pPIC9HV-rrVEGF- 
164 expression vector (Fig. 2) was transformed into E. coli. Positive clones were selected by 
means of ampicillin resistance. Eight of 64 colonies able to grow on ampicillin plates were 
sequenced. After verifying the nucleotide sequence of the insert using DNA sequencing (Fig. 
3) and a subsequent BLAST search, one colony was found identical with seven rrVEGF-164 
sequences published. The nucleotide sequence encoding the rrVEGF-164 (Genbank 
reference GQ423618) showed a 100% homology with the nucleotide sequence of rrVEGF- 
164 published by Conn el al. 1990 (24) (Genbank reference AAA41211) and Strausberg et al. 
2002 (25) (Genbank reference AAI68708).
Cloning and production of rat VEGF-164
After isolation and linearisation of the plasmid DNA of the positive clone with SalI, the 
competent P. pastoris GS115 cells were transformed with plasmid DNA by means of electro­
poration. The transformants were cultured in the absence of histidine and 6 colonies were
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picked and examined for rrVEGF-164 production. Western blot analyses indicated that 4 of 
the 6 clones produced rrVEGF-164 (data not shown).
Fig 2 Map of the rrVEGF-164 expression vector based on the pPIC9HV vector. MCS: multiple cloning site. 
The a-factor directs VEGF to the secretory pathway. EcoRI and NotI restriction sites were used to insert 
rVEGF-164 into the multiple cloning site. The ampicillin resistance gene (AMP) was used for E. coli trans­
formant selection. The histidine independent gene (His4) allows growth in the absence of histidine, and 
was used for P. pastoris transformant selection. The SalI restriction site was used to inactivate the His4 
gene and only a successful ligation results in an intact His4 gene.
Fig 3 Nucleotide sequence and the deduced amino acid sequence of the relevant part of P. pastoris 
rrVEGF-164 expression vector, indicating a-Factor Signal Sequence, the EcoRI restriction site, the rVEGF-
164 insert, the NotI restriction site and the polyhistidine-VSV tag. A stop codon was positioned between 
rVEGF-164 and NotI in order to produce VEGF without tags. The a-factor signal, the rVEGF-164, and the 
His/VSV tag are indicated by boxes. The a-factor primer is also indicated.
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Fig 4 Profile of fermentation process describing the % methanol feed, pH, % dissolved oxygen level and 
% glycerol feed in time (hours). In the culture phase a biomass of yeast cells was formed. In the fed- 
batch phase glycerol was accumulated in the yeast cells as a major carbon source. In the induction phase 
the VEGF-164 production was induced with methanol.
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Fig. 5 FPLC flow chart of the purification of rrVEGF-164 by heparin affinity chromatography. In green the 
elution buffers are indicated; viz. 10 mM phosphate buffer (pH 7.0) containing 1M NaCl or 2 M NaCl. The 
Y-axis indicates absorbance at \  =280 nm expressed in arbitrary units (AU). On the X-axis, the collected 
fractions (each containing 2 ml) are represented by the vertical dashed lines.
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Purification and identification of rrVEGF-164
From the small production screening one clone with a strong band on Western blot was 
selected and used for large scale production. After the fermentor run, the bulk cell mass was 
separated from the supernatant and the expressed rrVEGF-164 was purified from the super­
natant. Because rrVEGF-164 is a heparin-binding protein, the expressed product was purified 
with a heparin column. The rrVEGF-164 was present in the 1 M NaCl elution peak (Fig. 5). 
The rrVEGF-164 content in the pooled peak fractions was ~124 mg/L as determined by Lowry 
protein assay (22). Using non-reducing conditions, SDS-PAGE showed one broad band of 
about 48 kDa (dimer), whereas under reducing conditions a main band of about 24 kDa band 
(monomer) was observed (Fig. 6A). It was to be expected that on an SDS-PAGE gel dimeric 
and monomeric rrVEGF-164 migrate at 45 kDa and 23 kDa, respectively (26). Western blot 
analysis using an anti rat VEGF-164 antibody further indicated that the protein was rat VEGF- 
164 (Fig.6B). Under non-reducing conditions, the expressed rrVEGF-164 existed in the bio­
logically active form of a homodimer. Dimers of VEGF are disulphide-bridged, which is essen­
tial for the biological activity of VEGF-164 (5). These data indicate that rrVEGF-164 is 
produced as a disulphide-bridged dimer which can be purified to near homogeneity by 
heparin affinity chromatography.
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Fig 6 Analysis of produced rrVEGF-164 by SDS-PAGE and Western blot analysis. A) Coomassie Brilliant 
Blue staining; lane 1: markers; lane 2: rrVEGF-164 under non-reducing conditions (about 48 kDa); lane 3: 
rrVEGF-164 under reducing conditions (about 24 kDa). B) Western blot analysis of the produced rrVEGF- 
164; lane 1: markers; lane 2: rrVEGF-164 under non-reducing conditions (about 48 kDa); lane 3: rrVEGF- 
164 under reducing conditions (about 24 kDa). Figure A and B are both composite images of VEGF-164 
monomer and dimer products, taken from separate reducing and non-reducing gels respectively.
Biological activity of produced rrVEGF-164
The biological activity of the purified rrVEGF-164 was determined by a WST-1 
proliferation assay using human endothelial cells (HUVECs). HUVECs are generally used to 
evaluate the activity of VEGF from various species (16, 27). Already after 1 day, the 25 ng/ml 
content resulted in a three-fold increase in proliferation compared to medium without 
added VEGF (Fig 7A). After 3 days, the amount of proliferation at content of 12.5-25 ng/ml 
showed a three to five-fold increase (Fig 7B). We also compared our produced Pichia VEGF 
with commercial rrVEGF-164 which is produced in a mouse myeloma cell line. At amounts of 
12.5-100 ng/ml, the produced rrVEGF-164 showed a significantly higher proliferation than 
the commercial batch of rrVEGF-164 (p<0.05; Fig. 7A and B).
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Fig 7 Biological activity of the produced rrVEGF-164 and commercially available rrVEGF-164 analysed 
using a WST-1 assay. A) Proliferation after 1 day of culture. B) Proliferation after 3 days of culture. The 
proliferation without added VEGF was set to 100%. Results are mean ± SD for 3 separate experiments. 
All values were significantly increased compared to the control values. * Indicates p<0.05 when 
comparing produced and commercial rrVEGF-164.
The difference in activity for the commercial VEGF and our Pichia-derived VEGF might be 
due to the presence of inactive forms as influenced by the production method. Until now, 
both mouse myeloma cell lines and E. coli have been used to produce rrVEGF-164 commer­
cially. The myeloma and E. coli production methods can result in heterogeneity of molecules 
with variable biological activities (28). Additionally, for E. coli the expressed product is pre­
sent in inclusion bodies and in order to be active the protein must be refolded (dimerised) 
after purification. For rrVEGF-164 produced in P. pastoris, the protein has already been 
processed, including disulfide-linked dimers, before secretion into the cell medium. This pre­
processing can result in a potentially more homogeneous, more highly active population of 
the product.
CONCLUSIONS
In this study, we have cloned and expressed biologically active recombinant rat vascular 
endothelial growth factor (rrVEGF-164) in the yeast P. pastoris. Recombinant rat VEGF-164 
was successfully produced as an active dimer in a large quantity. The produced rrVEGF-164 
had a higher biological activity than commercially available growth factor (produced in a 
mouse myeloma cell line). The high level expression of biologically active recombinant rat 
VEGF-164 provides a useful tool for basic and applied research.
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ABSTRACT
INTRODUCTION An important issue in tissue engineering is the vascularisation of the 
implanted construct, which often takes several weeks. In vivo, the growth factors VEGF and 
FGF2 show a combined effect on both angiogenesis and maturation of blood vessels. There­
fore, we hypothesise that the addition of these growth factors to an acellular construct 
increases blood vessel formation and maturation. METHODS To systematically evaluate the 
contribution of each scaffold component with respect to tissue response and in particular to 
blood vessel formation, five porous scaffolds were prepared and characterised viz.: collagen, 
collagen with heparin, and collagen with heparin plus one or two growth factors (rrFGF2 and 
rrVEGF). Scaffolds were subcutaneously implanted in 3 months old Wistar rats. RESULTS Of 
all scaffolds tested, the one with a combination of growth factors displayed the highest 
density of blood vessels (type IV collagen) and most mature blood vessels (smooth muscle 
actin). In addition, no hypoxic cells were found in this scaffold at day 7 and 21 (hypoxia 
inducible factor 1-a). CONCLUSIONS These results indicate that the addition of both FGF2 
and VEGF to an acellular construct enhances an early mature vasculature. This opens 
prospects for (a-cellular) tissue-engineered constructs in conditions as ischemic heart 
disease or diabetic ulcers.
40
Increased angiogenesis and blood vessel maturation in acellular collagen-heparin-GF scaffolds
INTRODUCTION
A major problem in tissue engineered devices is the vascularisation of the construct. It 
usually takes several weeks for a construct to become fully vascularised (1). Vascularisation 
is important in several pathological conditions including ischemic heart disease (2) and 
diabetic ulcers (3). Impaired wound healing in case of diabetic ulcers occurs due to a lack of 
oxygen and nutrition to the cells and inadequate removal of waste products from the cells 
(4). Introduction of angiogenesis results in better healing of affected tissues (5).
In order to increase the vascularisation of tissue engineered constructs, several 
approaches have been employed. For instance, the pore size of the scaffold has been varied 
resulting in an optimum diameter for cellular adhesion and migration (~100 |am) (6). Further­
more, endothelial cells and fibroblasts have been included in gelatine-coated polystyrene 
scaffolds in order to initiate angiogenesis in vitro, resulting in sprouts prior to trans­
plantation (7). The addition of glycosaminoglycans and growth factors also proved to 
increase angiogenesis in vivo (1). However, it still takes about four weeks to develop 
sufficient vasculature.
Angiogenesis is a multifactor process, which is regulated by an interplay of a large 
number of factors. Angiogenesis can be set on by e.g. hypoxia (8). An important stimulating 
factor in angiogenesis is vascular endothelial growth factor (VEGF) which acts on the VEGF 
receptors (VEGFR). VEGF stimulates cells to produce matrix metalloproteinases (MMPs) that 
degrade the basement membrane and surrounding extracellular matrix. As a result, endo­
thelial cells proliferate and migrate towards the interstitium, where they start sprouting. 
Subsequently, pericytes proliferate and migrate towards the newly formed sprouts and 
induce maturation by forming a single cell layer around the sprout (9,10). The administration 
or overexpression of single VEGF isoforms in animal models results in angiogenesis, but the 
newly formed blood vessels may be leaky and phenomena such as oedema, inflammation 
and hemorrhagic ulcers have been reported (9).
Another growth factor known for its angiogenic potential is fibroblast growth factor 2 
(FGF2). This growth factor stimulates endothelial cells to produce both MMPs and VEGF and 
increases VEGFR expression. FGF2 also stimulates endothelial cell migration, pericyte 
attraction and matrix deposition (11). Local administration of this growth factor in a rabbit 
ear chamber model induced angiogenesis, although some animals showed bleeding vessels 
and full vascularisation required at least three weeks. Clearly, the administration of one 
growth factor is not sufficient to create well-developed mature blood vessels. Few authors 
have studied the combined administration of growth factors. Tumour cells, transfected with 
VEGF and/or FGF2, need both VEGF and FGF2 to form blood vessels. Similar synergistic 
effects were found by local administration of VEGF and FGF2 in a rabbit ischemic hind limb 
resulting in a higher capillary density and capillary vs. muscle fibre ratio than either VEGF or 
FGF2 alone (14).
In this study, we tested the hypothesis that the combined application of recombinant rat 
VEGF-164 (rrVEGF) and recombinant rat FGF2 (rrFGF2) increases angiogenesis in acellular 
collagen-heparin scaffolds for tissue engineering. For that purpose, scaffolds consisting of 
combinations of type I collagen, heparin, FGF2 and VEGF were constructed, characterised 
and evaluated for in vivo tissue response after subcutaneous implantation in adult Wistar 
rats.
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MATERIALS AND METHODS
Materials
Unless stated otherwise all chemicals were purchased from Merck Chemicals (Darmstadt, 
Germany). Type I collagen was purified from bovine achilles tendon using diluted acetic acid, 
NaCl, urea and acetone extractions (15). Heparin was purchased from Sigma Chemical Co. (St 
Louis, MO, USA). Recombinant rat FGF2 was produced in E. coli M15 PQE16 and 
recombinant rat VEGF-164 in P. pastoris GS115 (1).
Preparation of scaffolds
Five different scaffolds were prepared:
- COL: type I collagen only,
- COLH: type I collagen with heparin,
- COLHF: type I collagen with heparin and FGF2,
- COLHV: type I collagen with heparin and VEGF,
- COLHFV: type I collagen with heparin, FGF2 and VEGF.
The scaffolds were prepared by freezing a 0.8% collagen suspension in diluted acetic acid 
at -20°C (1,16) and subsequently lyophilising in a Zirbus lyophiliser (Bad Grund, Germany). All 
scaffolds were chemically crosslinked with and without 2.75% heparin for 4 h with 33 mM 1- 
ethyl-3-dimethyl aminopropyl carbodiimide (EDC) and 6 mM N-hydroxysuccinimide (NHS) in 
50 mM 2-morpholinoethane sulphonic acid (pH 5.0) in the presence of 40% ethanol. After 
reaction, the scaffolds were washed in 0.1 M Na2HPO4, 1 M NaCl, 2 M NaCl and 
demineralised water. Scaffolds (2 punches per ml, ± 1,5 mg each) were incubated for 60 min 
in 7 Mg growth factor (FGF2 or VEGF) per ml phosphate buffered saline (PBS) (pH 7.2) and 
washed in PBS (1). For the combination of both growth factors, 3.5 Mg/ml of FGF2 and 3.5 
Mg/ml VEGF were used.
Characterisation of scaffolds
Scanning electron microscopy (SEM) was used to analyse the ultrastructure of the scaf­
folds. Scaffolds were mounted on stubs and sputtered with an ultrathin layer of gold in a 
Polaron E5100 SEM coating system, and analysed with a JEOL JSM-6310 scanning electron 
microscope at 15 kV.
The amine group content of the scaffolds was analysed using 2,4,6-trinitrobenzene 
sulphonic acid to determine the extent of crosslinking (17).
The heparin content of the scaffolds was determined by a hexosamine assay using 
p-dimethyl-aminobenzoaldehyde (15).
The amount of growth factor bound to the scaffold was determined by western blotting 
(18) with antibodies against FGF2 (1:2000) and rat VEGF (1:1000) and peroxidase-conjugated 
secondary antibodies visualised with a chemiluminescent detection kit (ECL) (Amersham Bio­
sciences). Gene Tools (Syngene, Cambridge, UK) was used to analyse the intensity of the 
bands. 0-100 ng growth factor was used as a standard curve. Scaffolds without growth 
factors were taken as controls.
Immunofluorescence microscopy was used to determine the distribution of type I 
collagen, heparin, FGF2 and VEGF in the scaffolds, as described (20) (for dilutions see Table 
1). Omission of the primary antibody was taken as a negative control.
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Implantation of scaffolds
NIH guidelines for the care and use of laboratory animals (NIH publication 85-23 Rev. 
1985) were observed. The study was approved by the Ethics Committee of the Radboud 
University Nijmegen. Wistar rats (male, 3 months) were purchased from Harlan (Horst, The 
Netherlands). The rats were housed per 2, fed pelleted diet (RMH-B 10 mm) and water ad 
libitum. The rats were anaesthetized with isoflurane. After disinfection, 4 subcutaneous 
pockets were made on both sides of two midline incisions on the back. Scaffolds (0 6 mm) 
were washed in 70% ethanol (4x 30 min) and sterile PBS (8x 30 min) and placed in the pock­
ets at about 1 cm of the incision. Each rat received 4 implants (2 different scaffolds). At day 
3, 7 and 21, the implants with surrounding tissue were removed. The explants were divided 
in halves; one half was processed for conventional histology and the other for immune- 
histochemistry.
Processing of explants
Conventional histology: to study the cellular reaction, paraffin sections were cut and 
haematoxylin-eosin stained (21). Histology of the scaffolds was evaluated independently by 
at least two experienced investigators.
Immunostaining: To study formation, maturation and functionality of blood vessels, 
sections were stained with specific antibodies. Type IV collagen (COL IV) was used to 
manually determine the total area of blood vessels (22). The total area of blood vessels was 
expressed as a percentage of the total implant size. Smooth muscle actin (SMA) was used to 
study the level of maturation of the newly formed blood vessels (23). The total area of SMA- 
positive blood vessels was expressed as a percentage of the total area of blood vessels. 
Hypoxia inducible factor 1-a (HIF1-a) was used to determine the number of hypoxic cells in 
the scaffold (24). The amount of HIF1-a-positive cells was expressed as a percentage of the 
total number of cells (on average, 500 cells were counted). Values were compared using the 
Student's t-test and p< 0.05 was considered to be statistically significant.
Immunofluorescence assay, Frozen sections were cut and incubated with antibodies for 
collagen type IV and smooth muscle actin as described (20) (for dilutions see Table 1).
Peroxidase-antiperoxidase method, the peroxidase-antiperoxidase method was used to 
immunolocalise molecules (hypoxia inducible factor 1-a and smooth muscle actin) in paraffin 
sections. 5 |am sections were deparaffinised and incubated as described (21) (for dilutions 
see Table 1).
Table 1. Antibodies used for Immunohistochemistry
P rim a ry  an tibo dy dilu tion S e co n d a ry  an tibo dy dilu tion T e rtia ry  an tibo dy dilu tion
M ou se  an ti bo v in e  typ e  I co lla ge n A 1:2000 A le xa  48 8  lab e lled  go a t an ti m ou se  F 1:200
An ti he pa rin  (H S 4C 3 ) * 1:5 M ou se  anti V S V -tag  (P 5D 4 ) * * 1:10 A le xa  59 4  labe lled  go a t anti m ou se  F 1:200
G o a t an ti rat F G F 2  A 1:500 A le xa  48 8  lab e lled  do n ke y  anti g o a t F 1:200
G o a t an ti rat V E G F  B 1:50 A le xa  48 8  lab e lled  do n ke y  a n ti g o a t F 1:200
G o a t an ti hu m an typ e IV co lla ge n C 1:50 A le xa  48 8  lab e lled  do n ke y  anti g o a t F 1:200
M ou se  an ti-a  sm oo th  m usc le  actin  A 1:400 A le xa  48 8  lab e lled  go a t an ti m ou se  F 1:200
M ou se  an ti-a  sm oo th  m usc le  actin  A 1:400 G o a t an ti m ou se  IgG  E 1:50 M o u se  p e ro x id a se -a n tip e ro x id a se  E 1:500
M ou se  an ti h u m an  H IF 1 -a  D 1:1000 G o a t an ti m ou se  IgG  E 1:50 M o u se  p e ro x id a se -a n tip e ro x id a se  E 1:500
* Single chain variable fragment (ScFv) antibody against heparin (19)
** Antibody against the VSV-tag of the ScFv (19)
A: Sigma Chemical Co (St. Louis, Mo, USA), B: R&D systems (Minneapolis, MN,USA), C: Southern Bio­
technologies (Birmingham, AL, USA), D: Abcam (Glostrup, Denmark), F: Molecular probes (Leiden, The 
Netherlands)
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RESULTS
Scaffold characteristics
The morphology of the scaffolds was analysed by SEM (Fig. 1A, B). Rounded pores were in 
the range of 75 to 125 Mm. The scaffold was chemically crosslinked with EDC and NHS to 
covalently bind heparin. During crosslinking, an amine group reacts with a carboxylic group 
and hence the extent of crosslinking was evaluated by analysing the remaining free amine 
groups. About 50- 60% of the amine groups were used for crosslinking (Table 2). The amount 
of heparin covalently bound to the scaffold was ~ 68 Mg/mg scaffold, as determined by 
hexosamine assay.
The amount of FGF2 that bound, analysed by western blotting and Gene Tools, was 1.6 ± 
0.2 Mg/mg scaffold. For VEGF, it was 1.0 ± 0.3 Mg/mg scaffold. When both growth factors 
were present in the dipping solution, 1.0 ± 0.2 Mg FGF2 and 0.7 ± 0.3 Mg VEGF bound per mg 
scaffold (Fig. 2 and Table 2).
The distribution of the different components in the scaffolds was visualised using 
immunofluorescence and revealed that heparin, FGF2 and VEGF were equally distributed 
throughout the scaffold (Fig. 1C-G).
CONTROL
G
Fig. 1 Microscopical evaluation of the different scaffolds. Scanning electron micrograph of a cross­
section of COL (A) and COLH scaffold (B). Immunolocalisation of type I collagen (C), heparin (D), FGF2 (E) 
and VEGF (F) in a COLHFV scaffold. Bar (A, B) is 100 Mm; bar (C-G) is 50 Mm.
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Table 2. Biochemical properties of the prepared scaffolds.
Scaffold Crosslinked with Amine group content Heparin content FGF2 content VEGF content
EDC/NHS [nmol/mg scaffold] [ug/mg scaffold] [pg/mg scaffold] [pg/mg scaffold]
COL - 337 ± 24
COL + 166 ± 16
COLH + 180 ± 9 68 ± 3
COLHF + 188 ± 7 70 ± 4 1.6 ± 0.2
COLHV + 193 ± 24 65 ± 4 1.0 ± 0.3
COLHFV + 186 ± 13 63 ± 5 1.0 ± 0.2 0.7 ± 0.3
Biochemical analysis of the prepared scaffolds consisting of type I collagen (COL), type I collagen and 
heparin (COLH), type I collagen, heparin and FGF2 (COLHF), type I collagen, heparin and VEGF (COLHV) 
and type I collagen, heparin, FGF2 and VEGF (COLHFV). The amine group content was determined using 
2,4,6-trinitrobenzene sulfonic acid (17); the heparin content using p-dimethyl-aminobenzoaldehyde 
(15), and the amount of FGF2 and VEGF by western blotting (18), quantitatively analysed with Gene 
Tools. The results are the mean ± SD of 3 independent experiments.
□  0 20 40 SOH I  113 vee
Fig 2 The amount of FGF-2 and VEGF bound to collagen-heparin scaffolds measured by western blotting 
and band analysis. A) Western blot of the results of the scaffolds; lane COLHV: scaffold incubated in 7 
Mg/ml VEGF, lane COLHFV: scaffold incubated in 3.5 Mg/ml FGF2 and 3.5 Mg/ml VEGF, lane COLHF: 
scaffold incubated in 7 Mg/ml FGF2. B: The standard curve (0-100 ng) (B) of VEGF. Similar results were 
found for the standard curve of FGF2.
Cellular response to scaffolds
A systematic survey using five different types of scaffolds allowed us to evaluate the 
contribution of the different components. Cellular events are summarised in Table 3. At day 
3, COL and COLH scaffolds showed minor infiltration of granulocytes and macrophages at the 
outer part of the scaffold, whereas COLHF and COLHV showed a moderate amount of 
macrophages, fibroblasts and some granulocytes further in the scaffold. COLHFV showed a 
moderate amount of granulocytes, macrophages and some fibroblasts throughout the 
scaffold (Fig. 3). A thin layer of capsule surrounded all implants. At day 7, no granulocytes 
were present in the scaffolds anymore. Few giant cells were found at this time point. The 
cellular response to COL and COLH included a moderate amount of macrophages and some 
fibroblasts further in the scaffold. COLHF and COLHV showed a moderate amount of macro­
phages and fibroblasts throughout the scaffold and some non-phagocytic cells were present. 
A larger amount of macrophages and fibroblasts accompanied by some non-phagocytic cells 
were found throughout the COLHFV scaffold. All scaffolds contained a thin layer of capsule 
around the implants. At day 21, macrophages and non-phagocytic cells were present 
throughout COL and COLH scaffolds. A larger amount of macrophages, giant cells, fibroblasts 
and non-phagocytic cells was found throughout the COLHF, COLHV and COLHFV scaffolds. All 
scaffolds contained a capsule layer around the implants.
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Table 3. Tissue response to the implanted scaffolds.
Scaffold Days after 
implantation
PMNs * Phagocytic cells** Non-phagocytic 
cells ***
Fibroblasts
COL 3 + + - -
l - ++ - +
21 - ++ + +
COLH 3 + + - -
l - ++ - +
21 - ++ + +
COLHF 3 + ++ - +
l - ++ + ++
21 - +++ ++ ++
COLHV 3 + + - +
l - ++ + ++
21 - ++ ++ ++
COLHFV 3 ++ ++ - +
l - +++ + +++
21 - +++ ++ ++
Cells were scored from not present (-) to abundantly present (+++).
The absolute numbers of PMNs and non-phagocytic cells are lower than for phagocytic cells. 
* PMNs = polymorphic nuclear cells, i.e. granulocytes.
** Phagocytic cells include macrophages and monocyte-derived giant cells.
*** Non-phagocytic cells include lymphocytes, plasma cells and mast cells.
Fig 3 Histological evaluation of scaffolds explanted at day 3. Haematoxylin-eosin staining of COL (A), 
COLH (B), COLHF (C), COLHV (D) and COLHFV (E). COL and COLH only showed some cells in the outer part 
of the scaffold, whereas the scaffolds with growth factors (COLHF, COLHV and COLHFV) also revealed 
cells in the centre of the scaffold. Bar is 100 Mm.
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Blood vessels
At day 3, no blood vessels were observed in the scaffolds, but blood vessels were found 
in the surrounding tissue. More blood vessels were found near COLHF, COLHV and COLHFV 
scaffolds compared to COL and COLH. This observation could also be made macroscopically 
from the red colour of the scaffolds at explantation. At day 7, no blood vessels were present 
in COL, whereas all other scaffolds contained blood vessels as shown by COL IV staining (Fig. 
4 and 5). COLHFV showed the largest blood vessel area (5.9% ± 1.6), COLHF (2.6% ± 1.9) and 
COLHV (2.3% ± 0.7) somewhat lower and COLH the least (0.9% ± 0.2). No significant 
differences were found between COLHV-COLHF and COLHF-COLH. SMA-staining was used as 
a marker for maturated blood vessels. The total area of SMA-positive blood vessels was ex­
pressed as a percentage of the total area of blood vessels (determined by COL IV staining) 
(Fig. 4 and 5). COLHFV showed most SMA-positive blood vessels (35% ± 4), more than 
COLHF (18.3% ± 7.4), COLH (17.2% ± 0.9) and COLHV (16.9% ± 2.2). No significant differences 
were found between COLHV-COLHF, COLHV-COLH and COLHF-COLH. At day 21, blood 
vessels were found in all scaffolds (Fig. 5). COLH (3.2% ± 0.9), COLHV (4.8% ± 1.8) and 
COLHFV (6.1% ± 1.2) had a significantly larger blood vessel area than COL (1.7% ± 0.8). 
COLHFV more than COLH and COLHF (3.2% ± 0.9), but no significant differences were found 
between COLHFV-COLHV, COLHV-COLHF, COLHV-COLH, COLHF-COLH and COLHF-COL. 
COLHFV (83.4% ± 4.9) showed a significant higher percentage of SMA-positive blood vessels 
than all other scaffolds (Fig. 6): COL (34.7% ± 10.5), COLH (32.3% ± 5.9), COLHF (34.2% ± 3.5) 
and COLHV (58.2% ± 12). No significant differences were found between COLHF-COLH, 
COLHF-COL and COLH-COL.
Hypoxia
At day 3, all scaffolds contained 97-98% HIF1-a-positive cells (hypoxic cells). The cells in 
the most outer region of the scaffolds, especially the scaffolds with one or two growth 
factors, stained less intense for HIF1-a, probably due to a partial supply of oxygen and 
nutrients from the surrounding tissue. At day 7, all scaffolds showed both HIF1-a positive 
and negative cells in the scaffold centre (Fig. 6). COLHFV (2.2% ± 0.9) had significantly less 
hypoxic cells than COL (36.6% ± 9.9), COLH (35% ± 13.5), COLHF (16% ± 9.2) and COLHV 
(10.4% ± 2.2). COLHF and COLHV had significantly less hypoxic cells than COL and COLH. At 
day 21, COLHFV (0.2% ± 0.04) had significantly less HIF1-a positive cells than COL (21.2% ± 
3.6), COLH (14.7% ± 2.6), COLHF (4.9% ± 1.4) and COLHV (4.0% ± 1.8) (Fig. 6). COLHF and 
COLHV had significantly less hypoxic cells than COL and COLH.
DISCUSSION
In tissue engineering, vascularisation of the transplanted constructs is often limited at 
early time points and this seriously hampers the survival of cells. Cells die due to lack of 
oxygen, nutrients and inadequate removal of waste products. This confines the size of 
tissue-engineered constructs to a maximum of a few cm2 (4). Generally, it takes several 
weeks for a construct to become fully vascularised. This slow development of blood vessels 
hampers wound healing or tissue regeneration in certain pathological conditions (3,5). A 
means to increase angiogenesis is to administer growth factors either by injection or pre­
ferably in a slow-release system such as a bioscaffold. Scaffolds can be built up from several 
components and in this study, we used highly purified type I collagen, heparin, recombinant 
rat FGF2 and recombinant rat VEGF.
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Fig 4 Macroscopical (A) and immunohistochemical evaluation of the scaffolds explanted at day 7 (B, C).
A) Macroscopical evaluation of a non-implanted scaffold at day 0 and explants at day 7 (COL, COLHV and 
COLHFV). Note the red appearance of the COLHFV scaffold. B) Immunohistochemical evaluation using 
type IV collagen staining of the scaffolds explanted at day 7. COLHFV showed the most and largest area 
of blood vessels compared to COLHV, COLHF and COLH. No blood vessels were found in COL at this time 
point. C) Immunohistochemical evaluation using smooth muscle actin staining of scaffolds explanted at 
day 7. COLHFV displayed the largest percentage of mature blood vessels compared to COLHV, COLHF 
and COLH. Arrows indicate SMA-positive blood vessels. Bar is 50 ^m.
Fig 5: Analysis of the blood vessels present in the scaffolds using COL IV and SMA staining. Scaffolds 
containing two growth factors showed both a larger total area of blood vessels and more mature blood 
vessels. A) The total area of blood vessels per scaffold was calculated from COL IV staining. At day 7, 
COLHFV had significantly more blood vessel area than all the other scaffolds. At day 21, COLHV had a 
significantly larger blood vessel area than all the other scaffolds with the exception of COLHV. * p<0.05.
B) The total area of mature blood vessels (staining positive for SMA) was expressed as a percentage of 
the total area of blood vessels. At day 7 and at day 21, COLHFV had a significantly higher percentage of 
SMA positive blood vessels than all the other scaffolds. * p<0.05.
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Fig 6 Immunohistochemical analysis of HIF1-a staining of cells in the scaffolds at day 3, 7 and 21. A) 
Photographs of COLHFV scaffold at day 3 and 7. COLHFV showed many hypoxic cells at day 3 and few at 
day 7. Inserts show that HIF1-a predominantly stains the nuclei of cells. Positive cells stain black and 
neg-ative cells stain blue. Bar is 10 Mm. B) Statistical analysis of the percentages of HIF1-a positive cells. 
At day 7 and 21, COLHFV had significantly less hypoxic cells than all other scaffolds. *p<0.05.
We have previously shown that collagen-heparin scaffolds can give sustained release of 
FGF2 (1). Therefore, five different, molecularly-defined, scaffolds were made, including 
collagen-heparin with and without one or two growth factors. Porous collagen scaffolds 
(containing pores of about 100 Mm) were prepared by lyophilisation and heparin was 
covalently attached to allow coupling of one or two heparin-binding growth factors (FGF2 
and VEGF). The amount of bound FGF2 resembled the amount found by Pieper et al., who 
used 125I-FGF2 to analyse the amount of bound growth factor (1). More FGF2 than VEGF was 
able to bind to collagen-heparin scaffolds, perhaps due to minor differences in their affinity 
for heparin (25,26). Less FGF2 and VEGF bound to the scaffold after incubation in a solution 
containing both growth factors, which is likely due to the lower concentration of each 
growth factor, 3.5 Mg instead of 7Mg/ml, in the dipping solution. The total amount of both 
growth factors present per mg scaffold was similar to the amount of bound FGF2 alone. This 
systematic approach allowed us to study the influence of single components on tissue 
response including blood vessel formation and maturation.
Many different factors, stimulators as well as inhibitors, are involved in angiogenesis, and 
they all have their own mechanism (9). VEGF is found to be one of the most important 
factors in angiogenesis. It stimulates endothelial cells by binding to VEGFR-2, thus inducing 
MMP production, proliferation and migration of the endothelial cells. FGF2 upregulates the 
expression of VEGF (25) and attracts pericytes, which form a single cell layer around the 
newly formed capillary, necessary to mature the blood vessel and to protect it from 
degradation (11). A HIF1-a/FGF2 amplification pathway in which FGF2 upregulates HIF1-a, 
leading to an angiogenic response has been reported (27). The complete mechanism behind 
the angiogenic response of FGF2, however, is still not fully understood (11).
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COL and COLH scaffolds showed a mild cellular response, whereas the scaffold with 
growth factors showed a higher influx of cells, mainly macrophages and fibroblasts and, at 
day 3, granulocytes. COLHFV attracted the largest amount of cells as expected. VEGF attracts 
macrophages, which on their turn produce VEGF as well as MMPs which release additional 
VEGF from the surrounding tissue (28). FGF2 stimulates proliferation and differentiation of 
granulocytes, endothelial cells, fibroblasts and many other cells. Granulocytes also produce 
MMPs that degrade the extracellular matrix and release VEGF and FGF2. Pieper et al. (1) also 
found that FGF2 addition to a scaffold attracted more cells. An increased cellular reaction 
may be necessary to trigger angiogenesis (29).
We found that the presence of VEGF or FGF2 alone gave blood vessel formation. The 
administration of a single growth factor (VEGF or FGF2) seems not sufficient to develop a 
normal vasculature (9,12). Indeed we show that a combination of VEGF and FGF2 is superior 
with respect to blood vessel formation and reduction of hypoxic conditions at early time 
points.
Our results emphasise that the combination of two growth factors enhances angiogenesis 
resulting in a higher area of blood vessels, similar to the findings of Ashara et al. (14) after 
injection of VEGF and FG2 in a hind limb ischemia model. The need for multiple growth fac­
tors was further investigated by Lascke et al. (30), who found that angiogenesis and blood 
vessel maturation could only be suppressed by complete inhibition of VEGF, FGF2 and 
platelet derived growth factor (PDGF). We do not need PDGF to develop mature blood 
vessels, perhaps because VEGF and FGF2 are capable to upregulate the production of PDGF; 
a combined administration of VEGF and FGF2 has been reported to be sufficient to develop 
mature blood vessels in the absence of PDGF (9).
To analyse whether the formed blood vessel were functional, we used a marker for 
hypoxia (HIF1-a). Under hypoxic conditions HIF1-a is accumulated and transported to the 
nucleus where it dimerises with HIF1-P to its active form (31). The staining revealed that the 
formed blood vessels were capable of supplying the infiltrated cells with sufficient oxygen. 
The scaffold with both FGF2 and VEGF showed almost no hypoxic cells from day 7 on. It usu­
ally takes 3 to 4 weeks for a construct to become fully vascularised (1,12). We show a huge 
reduction in the time needed to induce angiogenesis. This benefits tissue regeneration, es­
pecially when you consider that this process requires sufficient blood vessels to be present 
(32).
The combination of VEGF and FGF2 is capable of providing the scaffold with enough mature 
blood vessels to supply the cells of oxygen and nutrients at a very early time point. 
Bioscaffolds containing these several factors may be of use in several pathological condi­
tions, including ischemic heart disease or diabetic ulcers. For instance, in diabetic ulcers the 
most commonly used tissue engineered construct is Integra TM, a collagen based scaffold, 
which has the disadvantage that it takes several weeks to become vascularised which in­
creases the risk of infections (3,33). We propose that addition of appropriate growth factors, 
like FGF2 and VEGF, that increase blood vessel formation, could contribute to improved 
healing and reduction of hospitalization.
CONCLUSION
Our results indicate that the addition of both FGF2 and VEGF to collagen-heparin 
scaffolds leads to an early and well-developed vasculature. This opens new opportunities for 
the use of acellular scaffolds for tissue engineering.
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ABSTRACT
INTRODUCTION The aim of this study is to prepare a porcine model for femoral artery 
pseudoaneurysm (PSA) using a one-step surgical procedure without the need for micro­
surgery. METHODS This PSA model involves the preparation of an arteriovenous shunt 
between the femoral artery and femoral vein, where ~2 cm of the vein is segmented by 
proximal and distal closure using ligatures. The femoral PSA models were evaluated by 
angiography, Doppler auscultation and histology. RESULTS In 7 out of 8 pigs, angiography 
and Doppler auscultation showed that the PSA models were open and that there was com­
munication between the PSA model and the femoral artery. The mean length of the PSA 
model was 1.9 ± 0.3 cm (mean ± SD, n=7) with a neck region of 4 mm. Histology confirmed 
that PSA models were open and no thrombi were observed. The principal advantages of this 
model are the location of the PSA model, the short period of clamping, and the controllable 
size. CONCLUSIONS The pseudoaneurysm pig model is straightforward and reproducible, 
and may serve as a useful tool in the evaluation of interventional strategies for treatment of 
PSA's.
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INTRODUCTION
Pseudoaneurysms or false aneurysms are one of the most common arterial injuries. In 
contrast to a true aneurysm, the arterial wall is disrupted and a pulsatile hematoma is pre­
sent. Pseudoaneurysms are often found in the groin where the femoral artery is accessed for 
diagnostic and therapeutic procedures using arterial catheterisation (1, 2). If the arterial 
puncture site is not well sealed, blood will flow into the perivascular tissue, forming a local 
pulsatile hematoma. If kept undiagnosed or untreated, pseudoaneurysms may continue to 
expand in size, resulting in compression of femoral veins, arteries and nerves. This may 
eventually result in deep venous thrombosis, ischemia and rupture, causing limb pain and/or 
motor defects (3). Femoral artery pseudoaneurysms (PSA's) occur in 0.2-7.7% of patients 
after femoral arterial interventions (4-7), and is dependent on multiple factors, e.g. com­
pression, blood pressure, location of puncture, catheter/device size etc. Treatment by 
surgical intervention may cause complications such as haemorrhage, infection and scarring 
in addition to the risk of general anaesthesia. Other treatments aim for blood clotting within 
the femoral PSA, e.g. by manual compression (8), ultrasound-guided compression repair (9, 
10) and thrombin injection (11, 12). The clinical outcome of these treatments and their com­
plications (e.g. infections, emboli, thrombin-induced autoimmune response) have been well 
documented (2, 13-17). Nevertheless, a large animal model for femoral PSA may allow bet­
ter evaluation of the cause and potential prevention of procedural complications, 
particularly when utilizing non-surgical techniques for PSA.
In a PSA model, pulsatile arterial flow and controllable PSA dimensions (size of sac and 
neck) are crucial, and spontaneous coagulation must be avoided. Several experimental 
aneurysm models (e.g. pseudoaneurysm, intracranial aneurysm or carotid aneurysm) models 
using (micro)surgical techniques have been reported for rats (18), rabbits (19, 20) dog (21, 
22) and pigs (23, 24). In this study we have constructed a femoral PSA model by means of an 
arteriovenous shunt in the groin using procedures that were used in the cranial aneurysm 
models for dogs of Black et al. and Yapor et al. (25, 26). We used pigs, since these animals 
offer several advantages when constructing vascular models. They have a similar blood 
vessel morphology and coagulation characteristics compared to humans (27), and are 
appropriate for evaluation of human-sized therapeutic devices. Consequently, therapeutic 
investigations and possible side effects may be easy to extrapolate to the human situation. 
In addition, porcine vessels are large enough to manipulate surgically, so microsurgery is not 
necessary. Our aim was to develop a porcine femoral PSA model which closely resembles the 
morphological and hemodynamic characteristics of the human situation.
METHODS
Animals
This study was conducted under the supervision of veterinarians according to the NIH 
(National Institutes of Health) guidelines for the care and use of laboratory animals (NIH 
publication 85-23 Rev. 1985). The study was approved by the Ethics Committee (EC) of the 
Radboud University, Nijmegen, The Netherlands. Eight Landrace pigs of approximately 4 
months old, 4 male (mean body weight of 50.6 ± 6.8 kg, range 43.8 to 57.4 kg) and 4 female 
(56.0 ± 5.7 kg, range 50.2 to 61.7 kg), were used to introduce a pseudoaneurysm in the 
groin. The pigs were housed at the Central Animal Facility and fed a standard diet and water 
ad libitum.
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Surgery
One day before surgery, the animals received orally 4.4 mg/kg carbasalate calcium (Meda 
Pharma BV, Amstelveen, The Netherlands) and 1.5 mg/kg clopidogrel (Bristol-Myers 
Squibb/Sanofi Pharmaceuticals Partnership Bridgewater, NJ, USA) as interim anticoagulant 
and pain medication. At the day of surgery, the animals received orally 2 mg/kg carbasalate 
calcium and 0.75 mg/kg clopidogrel, which was repeated every 48 h for 4 days. For sedation, 
the animals were pre-medicated with an intramuscular injection of 10 mg/kg ketamine 
(Eurovet Animal Health BV, Bladel, The Netherlands), 1 mg/kg midazolam (Roche, Woerden, 
The Netherlands) and 50 Mg/kg atropine sulfate (Pharmachemie BV, Haarlem, The 
Netherlands). Each pig was then covered with a blanket and placed on a heating pad with 
administration of intravenous fluids through an auricular vein (lactated Ringer's solution 
containing per litre: 50 g dextrose, 6.0 g sodium chloride, 3.1 g sodium lactate, 1.8 g 
potassium chloride, 0.2 g calcium chloride-2H2O). Pigs were anesthetised with an intra­
venous administration of 2.5 mg/kg propofol (B. Braun Melsungen AG, Melsungen, Ger­
many). After endotracheal intubation, 2 L/min O2/N2O (2:1) containing 0.5% isoflurane (Bax­
ter International, Deerfield, IL, USA) was combined with a bolus of 0.3 mg/kg midazolam and
7.5 Mg/kg sufentanyl citrate (Janssen-Cilag BV, Tilburg, The Netherlands). The anaesthesia 
was maintained with 0.6 mg/kg/h midazolam, 10 Mg/kg/h sufentanyl citrate and 25 Mg/kg at­
ropine sulfate. Continuous monitoring was provided by electrocardiography, pulse oximetry, 
and CO2 and temperature registration.
A pseudoaneurysm was prepared in the groin using vascular surgery (Fig. 1). A bilateral 
oblique incision was made approximately 5 cm distal to the inguinal ligament, to isolate and 
expose the femoral artery and the femoral vein. Once isolated, 3-4 drops of 2% (w/v) 
lidocaine in isotonic solution (Holland Pharmaceutical Supply BV, Alphen a/d Rijn, The 
Netherlands) was applied to the surface of the femoral artery and vein to prevent 
vasospasm. Both artery and vein were located superficially and could be easily accessed. The 
artery and vein collaterals were then closed with 2.0 Vicryl (Ethicon, Norderstedt, Germany) 
suture knots. A segment of about 2 cm of both the femoral artery and femoral vein were 
temporarily closed using clamps (Fig. 2A). Vessel loops (Willy Rusch, Waiblingen, Germany) 
were used to position the artery and vein. In both femoral artery and femoral vein, a 4 mm 
longitudinal opening was made with #11 scalpel (Swann Norton, Sheffield, England). The 
artery was anastomosed to the femoral vein (side to side) with 6.0 Prolene running sutures 
(Ethicon) (Fig. 2B). Clamps were removed and after a 1 min observation, the PSA model was 
completed by closing the femoral vein both proximally and distally at the original site of the 
clamps using non-absorbable Serafil USP 3+4 ligatures (Serag-Wiessner, Naila, Germany) 
(Fig. 1 and Fig. 2C, D). The muscle layer and skin were closed with 2.0 Vicryl sutures. 
Amoxicillin (20 mg/kg/day, Centrafarm Services B.V., Etten-Leur, The Netherlands) was 
injected intramuscularly for 4 days to protect the animals from infections.
Evaluation
Food, water uptake and behaviour of the animals were monitored. Four days after the 
operation, the animals were anesthetised and the site of operation was exposed to evaluate 
the femoral PSA model. An ImexDopCT+ ultrasonic Doppler auscultator (Nicolet Vascular, 
Madison, WI, USA) was positioned directly on the PSA model and was used to evaluate the 
blood flow. Doppler auscultation was analysed with Audio spectrum software (SpectraPLUS, 
Pioneer Hill Software, Poulsbo, WA, USA).
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Fig. 1 Schematic overview of the pig femoral artery pseudoaneurysm (PSA) model. Collaterals were 
closed with ligatures (arrowheads). The femoral artery and femoral vein were anastomosed 'side to 
side' and a pulsatile vein segment was created by positioning ligatures proximally and distally on the 
femoral vein (arrows). The neck region of the PSA is indicated by the dashed rectangle
Fig. 2 Macroscopic overview of the preparation of a femoral artery pseudoaneurysm (PSA). A) Isolated 
and clamped femoral artery (left) and femoral vein (right). B) Anastomosing the artery and vein 'side to 
side'. Arrowheads point out the anastomotic site. C) View after removing the clamps from the 
anastomosed artery and vein. D) Final femoral PSA model after closure of the vein proximally and 
distally with suture knots (arrows). Double-headed arrow indicates the experimental femoral PSA 
model. Bar indicates 1 cm, a: femoral artery, v: femoral vein.
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Angiography was performed to analyse the blood flow qualitatively and to measure the 
size of the PSA model. Xenetix 300 iodinated contrast fluid (Codali Guerbet, Brussels, 
Belgium) was used as an intravascular flow tracer. Angiograms were made by accessing the 
contralateral site with a 6F sheath (Cordis, Miami, FL, USA). Thereafter, a 5F angiographic 
catheter (Boston Scientific, Natick, MA, USA) was introduced and positioned across the 
aortic bifurcation in the ipsilateral common femoral artery over a guide wire. All angiograms 
were performed with a Philips BV-25 C-arm image intensifier (Philips, Eindhoven, The 
Netherlands). Then, the catheter was removed and the wound was closed. After 10 days, the 
animals were re-anesthetised and a second angiogram was performed as described 
previously. The animals were sacrificed by an overdose of intravenous barbiturate. The 
femoral PSA model was inspected macroscopically, removed and immediately fixed in 4 % 
(v/v) paraformaldehyde in 100 mM phosphate buffer (pH 7.2) for at least 24 h at 4°C, and 
subsequently embedded in paraffin. Consecutive 5 Mm sections were mounted onto glass 
slides, dewaxed in xylol and rehydrated through a graded series of ethanol and stained with 
Hematoxylin and Eosin (H&E) and Elastin von Gieson (EvG) (28).
RESULTS
In the present study, we prepared a porcine pseudoaneurysm model using a one-stage 
procedure by anastomosing the femoral vein to the femoral artery side-to-side (see Fig. 1 for 
a schematic overview). Fig. 2 shows the macroscopic images of the surgical preparation of 
the PSA model. The operation did not require microsurgery. The femoral artery and vein 
were easily accessible and allowed standardised creation of pseudoaneuryms with a 
standardised length (2 cm). With arteriotomy, using microscissors, it was possible to repro- 
ducibly construct 4 mm necked pseudoaneurysms. Only a short period of clamping (~15 min) 
was necessary. After removing the clamps, a palpable thrill associated with the arterioven­
ous shunt was noticed. Generally, no severe bleeding was observed. However, in two cases 
bleeding occurred which was stopped with an additional suture in combination with gentle 
compression. This did not affect the outcome of the femoral PSA model. When the ligatures 
were positioned both proximally and distally on the vein, a segment filled out readily with 
blood and distinct pulsation was observed. No additional bleeding complications occurred.
All animals remained healthy and did not develop symptoms that are related to the 
surgery, e.g. swelling or mobility problems. After 4 days, a pulsatile PSA model was present 
in 7 out of 8 cases. In one animal the PSA model had clotted, but no mobility or health prob­
lems were observed. Macroscopic analysis of the PSA model revealed that the average 
length was 1.9 ± 0.3 cm (mean ± SD, n=7) and width was 0.5 ± 0.1 cm (mean ± SD, n=7). Mac­
roscopic observation indicated the presence of a pulsatile mass. Doppler auscultation 
revealed an continues bruit (or murmur) within the PSA model for all 7 pigs (Fig. 3). This 
bruit is a low and "machine-like" sound throughout systole and diastole, which is typical for 
pseudoaneurysm conditions (29, 30).
Four days after PSA creation, the angiogram demonstrated a flow between the femoral 
artery and the PSA model. The femoral PSA model remained patent during the study and 
resembled both dynamically and radiographically a pseudoaneurysm in the human situation, 
especially with regard to the morphology (Fig. 4A) (31). At day 10 (prior to sacrifice), both 
ultrasonic Doppler auscultation and angiography revealed that the femoral PSA model was 
open. After resecting the PSA, macroscopic analysis showed that both size and morphology 
were comparable to that observed at day 4 (Fig. 4B).
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Timafeeccjida)
Fig. 3 Doppler waveform indicating the bruit sound of the femoral artery pseudoaneurysm (PSA) and the 
pulsating sound from the femoral artery both proximally (left) and distally (right) from the femoral PSA 
model.
Fig. 4 Angiographic and macroscopic evaluation of femoral artery pseudoaneurysm (PSA). A) Angiogram 
of the right femoral artery localising the porcine femoral PSA model (arrow indicates arterial blood 
flow). B) Macroscopic image of resected PSA model with femoral artery at day 10. Bar indicates 1 cm in 
A and 0.5 cm in B. PSA: pseudoaneurysm, FA: femoral artery.
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Fig. 5 Light microscopy of a femoral artery pseudoaneurysm (PSA). A) Microscopic overview (H&E stain­
ing) of the connection between the femoral artery and the femoral PSA model (arrow indicates arterial 
blood flow). B) Inner wall of PSA model (H&E staining); arrows indicate the endothelial area. Inset: 
magnification of the area indicated by the rectangle. C) Inner wall of FAB (EvG staining) showing elastic 
lamina (arrow) and elastic fibers (E). Bar indicates 3 mm in A, 250 ^m in B and C, and 100 ^m in the inset 
of B. C:connective tissue, E: elastic fibers, FA: femoral artery, PSA: pseudoaneurysm, L: lumen of FAB.
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Histology confirmed that the femoral PSA model was open and effectively connected with 
the femoral artery (Fig. 5A). The femoral artery showed a normal structure. The inner layer 
of the wall of the PSA model consisted of the normal femoral vein structure; endothelial cells 
covering the elastic lamellae combined with smooth muscle cells and collagen. The outer 
layer of the PSA model consisted of connective tissue with blood vessels and a low number 
of fibroblasts (Fig. 5B and C). The EvG staining showed elastic lamina within the wall of the 
PSA model which were well preserved. No evidence of an inflammatory reaction was 
observed.
DISCUSSION
To evaluate novel and experimental femoral PSA treatments, their efficacy, safety and/or 
toxicological profile must be determined. In this respect, it is important to use a standard­
ised animal model which resembles the human situation as close as possible. Different 
aneurysm models have been developed in a variety of animal models. Most animal models 
rely on the surgical creation, typically by arteriotomy and vein graft placement (22, 24). Rat, 
rabbit, dog and pig models have been published, involving the connection of either a vein 
segment or a muscle cavity to the artery (18-21, 24).
In this study we have prepared and evaluated a model for pseudoaneurysms in the groin 
of the pig, the femoral artery pseudoaneurysm (PSA) model. It was our aim to create an easy 
to handle femoral PSA model that is appropriate for evaluation of endovascular treatments, 
e.g. coil embolisation, balloon techniques or thrombin injection. Although many 
experimental aneurysm models have been published, a large animal femoral PSA model has, 
to our knowledge, not been described. We used an one-step intervention procedure that 
was comparable with the method applied for cranial aneurysm models in dogs (25, 26), and 
adapted it for PSA model in the groin. The location and features of our surgically created PSA 
model resembles the human clinical situation. We used pigs since they closely match the 
hemodynamic and coagulation characteristics of humans (27), making the model suitable for 
translational studies.
In our femoral PSA model, an arteriovenous anastomosis was made and the adjacent vein 
was eventually closed both proximally and distally. We were able to reproducibly prepare a 
pseudoaneurysm with a narrow neck (4 mm), with standardised diameter and sac di­
mensions, making it possible to evaluate human sized devices. It is anticipated that by 
changing the distance of the ligatures the size of the PSA model can be controlled, thereby 
creating a range of femoral PSA models representing the clinical situation. It was also 
possible to prepare two femoral PSA models in one pig, which makes this model even more 
interesting both experimentally and economically.
The angiogram of our femoral PSA model was comparable with human pseudoaneurysm 
angiograms (31). Both angiography and Doppler auscultation confirmed that the PSA models 
were open, and demonstrated communication between the PSA model and the femoral 
artery. Doppler interrogation indicated a bruit representing the turbulent flow in the PSA 
model. Although many studies use only angiography, we think that the combination with 
Doppler can evaluate PSA model patency more thoroughly. Colour flow Doppler imaging 
would be even more useful then Doppler auscultation, but was not available at our animal 
facility.
Two key features which we used in our model to prevent aneurysm thrombosis were: 1) 
pre- and postoperative treatment with NSAIDs (non-steroidal anti-inflammatory drugs; car- 
basalate calcium and clopidogrel) to prevent platelet deposition, and 2) minimisation of the 
clamping time of both femoral artery and vein (~15 min) to reduce the risks of endothelial
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cell damage (32). A continuous layer of endothelial cells was present on the wall of the PSA 
model indicating that there was no major damage. This is of importance to prevent endo­
genous coagulation and is especially relevant for studies addressing the hemostatic 
effective-ness of treatment. When a continuous endothelial layer is absent, e.g. when ana­
stomosing a cauterised muscular cavity with the femoral artery, spontaneous blood clotting 
is a regular problem (20).
Although our model offers advantages over the current models, several shortcomings 
may exist. In our PSA model a vein segment was used with an intact endothelium. We chose 
for the intact endothelial layer to make the model especially suitable for study of the effect 
of hemostatic agents/devices proper. It should pointed out however, that the presence of an 
intact endothelial wall not truly mimics a human femoral aneurysm. In the human situation, 
PSA's are surrounded by interstitial tissue rather than an intact endothelium. In addition, in 
our PSA model, the neck region was fixed, whereas in human it may be variable. A next step 
in the validation of the PSA model is the evaluation of specific treatment modalities, e.g. 
thrombin injection or compression techniques'. Nevertheless, based on the translational 
characteristics of pigs, e.g. morphology and haemodynamics, we think this PSA model may 
be a promising pre-clinical model to study various aspects of PSA treatment both locally and 
systemically. Additionally, this PSA model in pig is appropriate to evaluate human sized 
devices. The model may also be helpful to determine the optimal dose of hemostatic agents 
or understand the mechanism in case of an arterial influx, and evaluate the safety and 
efficacy of new agents or devices. When doing so, a follow-up study with proper histology 
may be desirable to identify and clarify toxicological or systemic side effects.
Collectively, data indicate that the pig model for pseudoaneurysms is relatively straight 
forward, highly reproducible and approaches the human situation. Although we did not 
validate the utility of the PSA with known therapies, we anticipate that this large animal 
model allows the study of various aspects of PSA treatment both locally and systemically. 
The pseudoaneurysm model may offer new opportunities for interventional studies.
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ABSTRACT
INTRODUCTION Despite the efficacy of collagen in femoral artery pseudoaneurysm 
treatment, as reported in one patient study, its use has not yet gained wide acceptance in 
clinical practise. In the particular study, the collagen was not described in detail. To further 
investigate the potential of collagen preparations, we prepared and characterised highly 
purified injectable fibrillar type I collagen and evaluated its use for femoral artery pseudo­
aneurysm (PSA) treatment in vivo, using a pig model. METHODS Purified fibrillar type I 
collagen was characterised using electron microscopy. The effect of three different sterilisa­
tion procedures, i.e. hydrogen peroxide gas plasma (H2O2), ethylene oxide gas (EtO) and 
gamma irradiation, was studied on both SDS-PAGE and platelet aggregation. Different colla­
gen injectables were prepared (3%, 4% and 5%) and tested using an injection force test 
applying a 21 gauge needle. To evaluate the network characteristics of the injectable 
collagen, the collagen was suspended in phosphate buffered saline (PBS) at 37°C, and 
studied both macroscopically and electron microscopically. To determine whether the 
collagen induced hemostasis in vivo, a pig PSA model was used applying a 4% EtO sterilised 
collagen injectable, and evaluation by angiography and routine histology. RESULTS Electron 
microscopy of the purified type I collagen revealed intact fibrils with a distinct striated 
pattern and a length < 300 Mm. Both SDS-PAGE and platelet aggregation analysis of the ster­
ilised collagen indicated no major differences between EtO and H2O2 sterilisation, although 
gamma-irradiated collagen showed degradation products. Both 3% and 4% (w/v) collagen 
suspensions were acceptable with respect to the force used (< 50 N). The 4% suspension was 
selected as the preferred injectable collagen, which formed a dense network under physio­
logical conditions. Testing the collagen in vivo (n=5), the angiograms revealed that the PSA 
partly or completely coagulated. Histology confirmed the network formation, which was sur­
rounded by thrombus. CONCLUSIONS Collagen injectables were prepared and EtO sterilised 
without major loss of structural integrity and platelet activity. In vivo, the injectable collagen 
formed a dense network and triggered (partial) local hemostasis. Although optimisation is 
needed, an injectable collagen may be used as a therapeutic agent for femoral PSA treat­
ment.
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INTRODUCTION
A femoral artery pseudoaneurysm (PSA) is a complication which may occur after arterial 
puncture for invasive cardiovascular procedures. When an arterial puncture site fails to seal, 
arterial blood jets into the surrounding tissues and forms a pulsatile hematoma. In 0.2-7.7% 
of the femoral arterial interventions, a femoral PSA is formed that needs treatment (1-4). 
When a PSA is left untreated, rupture or distal embolisation may occur. PSA enlargement 
may give rise to pain, neuropathy and venous obstruction. Since spontaneous repair of 
larger pseudoaneurysms is unlikely, a reliable and easy method to induce local hemostatic 
clotting is desirable. Various techniques (e.g. ultrasound-guided compression repair, per­
cutaneous thrombin injection, balloon occlusion, stent-graft placement) have been used to 
stop arterial bleeding in order to replace standard compression treatment and shorten 
hospital stay (5-10). Thrombin treatment is highly effective. However, in some cases 
(especially complex pseudoaneurysms) it is not efficient and even contra-indicated. Contra­
indications for the use of thrombin injection are the wide and/or short necked pseudo­
aneurysms (11). Several cases have reported thrombin failure in these complex pseudo­
aneurysms (12-14). Particularly in these cases, injectable collagen may be an attractive 
agent, since collagen is highly viscous and collagen fibrils aggregate and deposit at the site of 
injection. In one study the potentials of injectable collagen for PSA treatment in patients was 
described, and a very high success rate was reported (15). To follow up on this study, we 
prepared a well characterised injectable collagen preparation, and evaluated its use in a 
porcine model for PSA treatment.
Collagen is a well known structural extracellular matrix protein. It has found ample usage 
as a biological material for medical applications indicating its versatility as a biomaterial, in­
cluding its use as a drug delivery device (16, 17) and as a matrix for the repair and 
regeneration of tissues (18-20). In addition it is used as an adjunct for hemostasis (21-23). 
Collagen-based plugs are widely used to manage the arterial puncture site and to prevent 
the extravasation of arterial blood (24, 25). When collagen comes in contact with blood, 
platelets become activated and their shape changes, resulting in the release of hemostasis- 
stimulating compounds, platelet adhesion and aggregation to the vessel wall. This process is 
also known as primary hemostasis (26, 27). Collagen is biocompatible and biodegradable 
which allows remodelling in the host after implantation. In addition, collagen can be 
fabricated in various physical forms like gels, films, and sponges. These characteristics, in 
combination with its hemostatic activity, make collagen a good alternative for current 
treatments of femoral PSA.
In 2002, Hamraoui et al. treated PSA patients with bovine fibrillar type I collagen aiming for a 
less invasive percutaneous treatment (15). According to this study, the use of collagen is a 
safe and effective strategy. To further elaborate on the use of collagen for PSA treatment, 
we prepared well characterised collagen fibrils, selected the optimal sterilisation procedure, 
and evaluated its use for the treatment of PSA using a recently described porcine model.
METHODS
Materials
Unless otherwise stated, chemicals were obtained from Merck (Darmstadt, Germany) and 
were of the highest purity available.
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Preparation of injectable fibrillar type I collagen
Fibrillar type I collagen was isolated from 6 months old bovine achilles tendon (deep 
flexor) applying extraction procedures using neutral salt solutions, chaotropic agents, dilute 
acid, and acetone (28). After purification, type I collagen was lyophilised using a Sublimator 
500II lyophiliser (Zirbus Technology, Bad Grund, Germany) and sterilised using either ethyl­
ene oxide gas (EtO; 24 h at 35-45°C and at 50-80% relative humidity; Sterigenics, Zoeter- 
meer, The Netherlands), hydrogen peroxide gas plasma (H2O2; 6 mg/l at 35°C for 30 min) or 
gamma irradiation (Gamma; 20 kGy from a 60Co source in a X-ray pallet irradiator (JS 9000; 
Isotron BV, 's-Hertogenbosch, The Netherlands)). Type I collagen suspensions were prepared 
by incubation of 3.0, 4.0 or 5.0 g type I collagen in 100 ml MilliQ water for 16 h at 4°C. The 
suspensions were homogenised (20 times on ice) using a Potter-Elvehjem homogeniser with 
an intervening space of 0.35 mm.
Characterisation of injectable fibrillar type I collagen
Scanning electron microscopy (SEM) was used to analyse the morphology and length of 
the purified collagen fibrils, and transmission electron microscopy (TEM) was applied to 
study the ultrastructure of the collagen fibrils. Collagen samples were frozen at -20°C and 
subsequently lyophilised. Poly-D-lysine coated glass inserts were incubated with collagen 
suspensions (~0.5 mg collagen/ml 0.25 M acetic acid), for 16 h at 4°C, washed 3 times with 
MilliQ water and air dried. Inserts were mounted on stubs and sputtered with an ultrathin 
layer of gold in a Polaron E5100 Coating System. The morphology of the collagen fibrils was 
studied in a Philips XL30 ESEM FEG apparatus at an accelerating voltage of 10 kV, and their 
lengths was studied with a JEOL JSM-6310 SEM (JEOL Ltd, Tokyo, Japan) at 15 kV; 100 fibrils 
were randomly measured at 500x magnification in 16 fields. The ultrastructure of the 
collagen fibrils was analysed in the diluted collagen samples using TEM. The samples were 
in-cubated on formvar-coated grids for 1 h at 21°C, washed with 0.1 M phosphate buffer (pH 
7.4), washed 2 times with MilliQ water, stained with 0.1% (v/v) uranyl acetate, and examined 
in a JEOL 1010 TEM (Tokyo, Japan).
The purity and intactness of the type I collagen before and after sterilisation was analysed 
using sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Samples 
were incubated at 95°C for 10 min under reducing conditions (5% (v/v) 2-mercaptoethanol) 
and analysed on a 8% (w/v) gel (29). Only potential impurities and degradation products will 
penetrate the gel since collagen fibrils are insoluble in sample buffer. Gels were stained with 
0.1% (w/v) Coomassie Brilliant Blue R-250 solution (ICN Pharmaceuticals, CA, USA), contain­
ing 50% (v/v) methanol and 10% (v/v) acetic acid.
To evaluate the network characteristics of the type I collagen under physiological 
conditions, the injectable collagen suspension (4% (w/v) in MilliQ), was injected in 
phosphate buffered saline (PBS, pH 7.4) at 37°C. In addition, to study this on the electron 
microscopical level, a collagen suspension (0.5% (w/v) in MilliQ water) was 1:1 diluted with 
PBS at 37°C. Collagen suspension (0.5% (w/v) in MilliQ water) 1:1 diluted in MilliQ water was 
used as a control. The collagen were analysed using the JEOL JSM-6310 SEM apparatus as 
previously described.
Injection characteristics of type I collagen suspension
To determine the force that is needed to inject type I fibrillar collagen suspension, an 
injection force test was performed (30). Different collagen suspensions (3%, 4% and 5% 
(w/v) in MilliQ water) were extruded from a 1 ml syringe with a 21 gauge needle (0 0.7 mm). 
The test was performed at a crosshead speed of 1.8 mm/s. The force was recorded by a MTS
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810 testing machine combined with a MTS 458.20 microconsole (MTS Systems Corporation, 
Eden Prairie, MN, USA).
Platelet aggregation
Platelet aggregation and thrombus formation is dependent on the structure of the 
collagen preparation (31). To assess the effect of sterilisation of the injectable collagen on 
the platelet activity, platelet aggregation was measured. The test was performed in a four- 
channel whole-blood aggregometer model 590 (Chrono-Log Corp, Havertown, PA, USA) 
measuring the impedance (%), that is increased proportional with the amount of platelet 
aggregation (31, 32). Briefly, whole blood was collected by vena puncture from a healthy 
volunteer and collected in 3.2 % (w/v) sodium citrate tubes (mean platelet count: 274-103 ± 
30-103/mI). Whole blood was diluted with PBS in a 1:1 ratio and incubated for 15 min at 37°C. 
Next, 10 Ml collagen suspension (0.05 mg/ml MilliQ water) was added to 1.0 ml diluted 
blood. All measurements were completed within 2 h from the blood draw. The platelet 
aggregation of non-sterilised collagen was set on 1 arbitrary unit (AU). Single way ANOVA 
was used for statistical analyses and p<0.05 was considered statistically significant.
Evaluation of injectable collagen in a porcine model for femoral artery pseudoaneurysm
To study the effectiveness of injectable collagen fibrils for treatment of pseudoaneurysm 
a pig model was used as described (33). This study was approved by the Ethics Committee 
(EC) of the Radboud University, Nijmegen, The Netherlands, and conducted under the 
supervision of veterinarians according to the NIH (National Institutes of Health) guidelines 
for the care and use of laboratory animals (NIH publication 85-23 Rev. 1985). The pigs were 
housed at the Central Animal Facility, Nijmegen, The Netherlands. The animals were fed a 
normal laboratory diet and water ad libitum. Briefly, the femoral artery and femoral vein in 
the groin of an adult pig were exposed and temporary clamped. A longitudinal arterio­
venous anastomosis (side to side) with a 4 mm opening was prepared and about a 2 cm 
segment of the femoral vein was used as PSA model after closing the femoral vein both 
proximally and distally using non-absorbable ligatures. The muscle layer and skin were 
closed. Amoxicillin (20 mg/kg/day) was injected intramuscularly for 4 days to protect the 
animal from bacterial infections. The animals received 2 mg/kg carbasalate calcium (Meda 
Pharma BV, Amstelveen, The Netherlands) and 0.75 mg/kg clopidogrel (Bristol-Myers 
Squibb/Sanofi Pharmaceuticals Partnership Bridgewater, NJ, USA) every 48 h for 4 days, as 
interim anticoagulant and pain medication.
Four days after construction of the PSA model, the animals were anesthetised and the 
operation site was re-opened to evaluate if the PSA model was pulsatile and to directly inject 
the collagen preparation. Using a 21 Gauge needle, 4% (w/v in MilliQ water) EtO sterilised 
4% (w/v) collagen suspension (100-200 Ml) was injected in the PSA compartment of 6 
individual pigs and the blood coagulation, host response and network properties of the 
collagen evaluated. Intraoperative femoral artery angiography was performed to document 
the blood flow in the PSA model before and after collagen injection. A contrast agent 
(Xenetix 300, Codali Guerbet, Brussels, Belgium) was used as an intravascular flow tracer. 
The angiogram was performed by accessing the contralateral site with a 6F sheath (Cordis, 
Miami, FL, USA). A 5F angiographic catheter (Boston Scientific, Natick, MA, USA) was 
introduced and positioned across the aortic bifurcation in the ipsilateral proximal common 
femoral artery over a guide wire. All angiograms were performed with a Philips BV-25 C-arm 
image intensifier (Philips, Eindhoven, The Netherlands). After removal of the catheters, the 
wound was closed. Six days after the initial evaluation, a second angiogram was performed 
and the animal was subsequently sacrificed by an overdose of intravenous barbiturate. The
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area of the pseudoaneurysm and the surrounding tissue was explanted and immediately 
fixed in 4% (v/v) formaldehyde in 10 mM phosphate buffer (pH 7.2) for 24 h at 4°C and 
embedded in paraffin. Consecutive 5 Mm sections were mounted onto glass slides, dewaxed 
in xylol and rehydrated through a graded series of ethanol. Hematoxylin and Eosin (H&E) 
staining was employed for histological evaluation.
RESULTS
Characterisation of type I collagen
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were 
used to analyse the morphology and ultrastructure of the purified type I collagen fibrils. Both 
SEM and TEM showed intact fibrils with distinct striated pattern, and no impurities could be 
detected (Fig. 1A and B). The striated pattern reflects the 3D organisation of (triple helical) 
collagen molecules within a collagen fibril. The measured length of collagen fibrils (Fig. 1C) 
indicated that fibril length was < 400 Mm, 75% of the fibrils being < 150 Mm.
SDS-PAGE was used to biochemically characterise the collagen before and after 
sterilisation (Fig. 2). For native type I collagen, SDS-PAGE showed a 1 and a 2 bands that are 
typical for type I collagen (Fig. 2; lane 1). No major differences were found before and after 
EtO sterilisation or H2O2 sterilisation (Fig. 2; lane 2 and 3). After gamma sterilisation how­
ever, a smear appeared on the gel, indicating collagen degradation products (Fig. 2; lane 4).
-s? $  ^  #  (¡S> & #  #■ t'P .Vp .-P .-P .'P k-P ,*P -Vp
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Fibril length (pm)
Fig. 1 Morphology and length of purified type I collagen fibrils. Scanning and transmission electron 
micrograph of purified type I collagen fibrils (A and B respectively), and the distribution of fibril length 
(^m) in the collagen preparation (C). Results are mean ± SD of 3 separate experiments. Bar in A is 1 Mm 
and inset 0.2 Mm. Bar in B is 0.2 Mm.
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Fig. 2 Effect of sterilisation procedure on the integrity of collagen. SDS-PAGE under reducing conditions 
of fibrillar type I collagen before (lane 1) and after (lane 2-4) sterilisation, viz.: ethylene oxide gas 
sterilisation (lane 2), hydrogen peroxide (H2O2) gas sterilisation (lane 3) or gamma irradiation (lane 4). 
The low molecular weight marker is visualised in lane 5. This is a combined image taken from two 
separate gels (lanes 1, 2 and 4 are from one gel). Note that especially after gamma sterilisation collagen 
degradation products are observed.
1.5
3
Non- EtO H2O2 Gamma 
sterilised
Fig. 3 Effect of sterilisation on platelet aggregation of fibrillar collagen. EtO: ethylene oxide gas 
sterilisation;H2O2: hydrogen peroxide sterilisation;Gam ma: gamma irradiation. Collagen before 
sterilisation was set on 1 arbitrary unit (AU). Results are mean ± SD for 3 separate experiments. 
Sterilised collagen showed no statistical significant differences in comparison to non-sterilised collagen 
(p>0.05).
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Platelet aggregation
A whole-blood platelet aggregation test was used to analyse the effect of sterilisation on 
platelet aggregation (in arbitrary units). The platelet aggregation of the native non-sterilised 
collagen was set to 1 arbitrary unit. The platelet aggregation of EtO, H2O2 and gamma were 
1.05 ± 0.14, 0.63 ± 0.14 and 0.73 ± 0.09, respectively (Fig. 3). Although EtO sterilised collagen 
was most comparable to the non-sterilised collagen, other sterilisation methods did also not 
significantly differ. EtO sterilised collagen was used for in vivo studies.
Characterisation of type I collagen injectability
An injection force test was performed to analyse the effect of different concentrations of 
type I collagen on injectability (Fig. 4A). The force was measured while extruding a 3%, 4% or 
5% (w/v) suspension from a 1 ml syringe through a 2 F (21 Gauge, 0.7 mm) needle. The 
suspensions required a force of 18 N, 19 N and 117 N, respectively (Fig. 4B). According to ISO 
regulations, both 3% and 4% (w/v) collagen suspensions are acceptable and can be used for 
manual injection (< 50 N according to ISO 7886-1:1997; 'Sterile hypodermic syringes for 
single use - Part 1: Syringes for manual use'). The 4% (w/v) collagen suspension was selected 
as the preferred injectable collagen suspension.
To analyse the network properties of the injectable type I collagen under physiological 
conditions, the 4% (w/v) collagen in MilliQ water (Fig. 5A) was applied to pre-heated (37°C) 
phosphate buffered saline (pH 7.4). Macroscopic evaluation indicated that the collagen 
formed a dense network immediate after extrusion in PBS (Fig. 5B). SEM analyses indicated a 
decrease in spacing between the collagen fibrils which is in line with aggregation of fibrils 
into a network (Fig. 5).
Fig. 4 Evaluation of injectability. A) Macroscopic image of the displacement test setup with type I 
collagen suspension in a 1 ml syringe. B) Graph of displacement test (1.8 mm/sec with maximal distance 
44 mm) of 3%, 4% and 5% (w/v) type I collagen suspension in a 1 ml syringe with a 2 F (0.7 mm) needle. 
On the Y-axis, force is given in Newton, and on the X-axis displacement is shown in mm. Results are 
mean ± SD of 3 separate experiments. The white arrow and white dashed line indicate the 1 ml syringe 
in the displacement set-up. The black arrow and dashed circle indicate the pressure plate.
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Fig. 5 Aggregation of injectable collagen under physiological conditions. Macroscopic images of 4% (w/v) 
type I collagen suspension in MilliQ water (A) and the network that was formed directly after injection of 
the type I collagen in pre-heated (37°C) phosphate buffered saline (PBS, pH 7.4) (B). Scanning electron 
microscopical images after applying a 0.5% (w/v) collagen suspension in MilliQ water or in PBS, resulting 
in an open fibril network (C) and an aggregated fibril network (D) respectively. Under physiological 
conditions (PBS, 37°C), the collagen fibrils formed a dense network. Arrows in A and B indicate the ag­
gregated type I collagen suspension. Arrowheads for D indicates the aggregated collagen fibrils. Bar is 10 
^m in C and D.
Evaluation of injectable collagen in a porcine model for femoral artery pseudoaneurysm
No complications due to the surgery were observed. In 1 of 6 cases, the femoral PSA 
model clotted directly after the operation and this model was excluded from the experi­
ment. No bleeding complications occurred as a result of surgery.
Four days after surgery, the PSA was evaluated with angiography before and after 
collagen injection. When the PSA model was open (Fig. 6A), 100 to 200 Ml 4% (w/v) type I 
collagen in MilliQ water was locally injected. In 4 of the 5 cases, the PSA model partly or 
completely coagulated within approximately 5 min after type I collagen injection, which was 
confirmed with angiography (Fig. 6B). In 1 case, both femoral artery and PSA coagulated. In 
this case, both femoral arteries were found open 6 days after injection leaving the PSA nicely 
closed (data not shown). After cross-sectioning the injected PSA, both the collagen and the 
thrombus were macroscopically visible and could be localised (Fig. 7).
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Fig. 6 Angiograms of the porcine femoral PSA (animal no. 6) at day 4 before collagen injection (A) and at 
day 10 (6 days after collagen injection) (B). Tweezers were positioned on the PSA segment (white arrow­
heads). In A, the PSA was open. In B, it was closed after collagen injection. FA: femoral artery. White 
arrows indicate the direction of arterial blood flow in the femoral artery.
Fig. 7 Macroscopic image of cross-sectioned PSA model, 6 days after collagen injection (animal no. 1, 
day 10). FA: femoral artery; PSA: pseudoaneurysm model with thrombus; c: injected type I collagen 
suspension (4% (w/v) in MilliQ water). The white dashed lines indicate the boundary of the PSA wall. Bar 
indicates 5 mm.
Fig. 8 Microscopic images of coagulated PSA model (luminal site) 6 days after type I collagen injection. 
Hematoxylin-eosin stained sections showed a clotted PSA filled with type I collagen (c) and coagulated 
blood cells (black arrows) (A, B). The wall of the PSA is indicated by dashed line (A). Leukocytes were 
found within the collagen network (white arrows) (B). c: collagen network. Bar indicates 500 ^m in A 
and 50 ^m in B.
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Histological evaluation
Six days after injection, a minor infiltration of inflammatory cells was observed (Fig. 8A). 
Specimens demonstrated a prominent thrombus and partial leukocyte infiltration towards 
the centre of the thrombus (Fig. 8B). The PSA wall was clearly visible and the injected 
collagen was observed in a network which appeared to be interconnected with the throm­
bus.
DISCUSSION
Collagen is well-known for its hemostatic activity, and has been widely used as a 
biodegradable plug to prevent hemorrhagic complications after arterial puncture, i.e. cathe- 
terisation or coronary angioplasty (34, 35). To our knowledge, only one study describes the 
use of collagen treatment after femoral PSA occurrence (15). Despite the reported efficacy 
of this study (97%), its use has not currently gained wider acceptance (21). However, the 
promising results of this study warrant further investigations to the use of collagen for PSA 
treatment.
Compared with thrombin there may be several additional values for use of collagen for 
(complex) PSA treatment. The first advantage may lay in its physico-chemical properties. 
With fibrillar type I collagen as an injectable, the consistency of the material is important. 
Collagen swells at low pH (36), making it possible to prepare a suspension or paste which can 
be injected. When the pH of the collagen suspension was increased to a physiological range 
(pH 7.4), the collagen fibrils formed a dense network. After applying the injectable collagen 
in the PSA model, fibrils aggregated and concentrated at the site of injection. Leukocytes in­
filtrated this collagen network, which is commonly found after applying collagenous bio­
materials in vivo (37). The consistency and the ability to form a network may be an 
advantage to reduce the risk of arterial influx of collagen fibrils. In addition, complex 
pseudoaneurysm have been described as contra-indications for thrombin treatment (11). 
Several cases reported thrombin failure in these complex pseudoaneurysms (12-14). The 
soluble thrombin may quickly diffuse through the wide neck of the pseudoaneurysm toward 
the lumen of the artery. In most cases these complex pseudoaneurysms need to be revised 
surgically. Especially in such cases, injectable collagen can be an attractive agent, since 
collagen is highly viscous and collagen fibrils aggregate and deposit at the site of injection, as 
shown in this study. The pseudoaneurysm model used in this study involves the preparation 
of an arteriovenous shunt between the femoral artery and femoral vein, where ~2 cm of the 
vein is segmented by proximal and distal closure using ligatures. This model presents a com­
plex pseudoaneurysm (with a relative wide opening (~4 mm) (33)) and makes the 
experimental model highly challenging with respect to pseudoaneurysm treatment.
A second issue may be the difference in immunogenicity between thrombin and collagen. 
There are several reported cases of immune complex reactions to bovine thrombin resulting 
in antibody formation. Although less for recombinant human thrombin (38), the antibodies 
may cross-react with the coagulation cascade, resulting in factor inhibition and clinical 
coagulopathy. 40% to 66% of patients who underwent cardiac surgery and 20% of patients 
who underwent neurosurgery developed bovine thrombin-associated factor V anti-bodies 
(39). This complication may be overcome by the use of collagen, since fibrillar bovine 
collagen is almost non-immunogenic.
Other advantages may relate to technical issues. The injectability of collagen is critical for 
its clinical performance and for patient comfort, e.g. in case of the use of collagen as a 
dermal filler (40). Especially for percutaneous PSA treatment, it is important that the agent
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can be injected through a needle with a limited diameter. In the clinical study of Hamraoui et 
al., a 1% (w/v) collagen suspension was injected through a relatively large 9F (0 3 mm) 
needle which may come with discomfort for the patient. In our suspension the collagen con­
tent was higher (4% (w/v)) and could be injected through a 2F (0 0.7 mm) needle, which is 
comparable with the procedure using thrombin injections (0 0.6 mm) (21). In addition, one 
well known technical difficulty in the use of thrombin is blood clotting inside the needle tip 
resulting in injection problems (41). With injectable collagen we did not observe this pro­
blem. The high consistency of the collagen may prevent the entrance of blood into the 
needle and subsequent clot formation.
Proper sterilisation is an important issue when using injectable collagen for medical 
applications. The injectable collagen must be supplied as a sterile product, but the efficacy of 
the collagen must not be compromised by the sterilisation technique. It has been described 
that techniques like gamma irradiation affect the structural properties of the collagen fibrils 
(42, 43). This may adversely affect the platelet aggregation and thrombus formation. For this 
reason, we tested different sterilisation techniques, and evaluated both biochemical and 
primary hemostatic characteristics. Both EtO and H2O2 sterilised collagen did not 
compromise the integrity of the collagen. We selected EtO for its tendency to have less in­
fluence on collagen-induced platelet aggregation In vivo, the injectable collagen suspension 
did induce local hemostasis within an approximate 5 min clotting time, but this was often 
partial. However, in one case we found that both the femoral artery and the PSA coagulated 
after collagen injection. Although the artery was open after 6 days, it demonstrates the ex­
isting risk of injecting hemostatic agents in femoral PSA. It has been described that a percu­
taneous thrombin injection in a femoral PSA, may be associated with an increased risk of 
thrombus extension (44). For thrombin injection, various methods are known in order to 
decrease this risk, e.g. directing the needle away from the PSA neck (9) or placing a balloon 
in the PSA neck (45). In case of high risk (complex) PSAs, these methods may also prevent 
the risk on distal embolisation when using injectable collagen. Particularly for the complex 
femoral PSA treatment, it might be attractive to combine collagen fibrils with thrombin to 
not only initiate the primary hemostasis, but also induce the secondary hemostasis (clotting 
factor mediated). Although not tested in this study, such an approach has been successful in 
giant splenic artery pseudoaneurysm treatment (46).
In view of our results, we conclude that an EtO sterilised, injectable 4% collagen could be 
prepared with defined structural characteristics and platelet activity. In vivo, the injectable 
collagen formed a dense network, which was (partially) hemostatic active. Injectable 
collagen may be an effective therapeutic alternative for current femoral PSA treatment, but 
additional studies are needed to prove its efficacy.
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ABSTRACT
Collagen scaffolds have been widely used as biomaterials for tissue engineering. In 
general, application of scaffolds requires surgery. In this study, we describe a new and 
simple technique to prepare porous micro-scaffolds from type I collagen fibrils which can be 
injected, thus preventing surgery. The size of the micro-scaffolds could be easily controlled 
using sieves with varying cut offs. EDC/NHS crosslinking was essential to stabilise the 
collagen micro-scaffolds. Micro-scaffolds were highly porous and could be injected through 
small diameter needles (18-21 Gauge). Collagen micro-scaffolds may be used as injectables 
for the local delivery of effector molecules and/or cells, thus creating specific niches to 
enhance local tissue regeneration.
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INTRODUCTION
A wide range of collagen-based biomaterials have been used for tissue engineering 
applications. (1-4). Collagen is often applied because of its biodegradability and biocompati­
bility, in addition to its good mechanical characteristics. Implantation of collagen scaffolds 
generally comes with surgery and introduces some risk of complications (e.g. infection, 
tissue damage). The availability of stable injectable scaffolds would facilitate (local) tissue 
regeneration without the need for surgery. Injectable porous micro-scaffolds may be 
attractive delivery vehicles for cells and effector molecules, which will further increase the 
applicability of collagen.
Injectable collagen particles have been developed for drug delivery (5, 6), or as 
thrombotic agents (7-9) combined with antibiotics delivery (10). However, highly porous 
micro-scaffolds prepared from native collagen fibrils for tissue engineering have not been 
reported. In this study, we introduce a straightforward technique to prepare stable collagen 
micro-scaffolds of different sizes, with good injectability, and discuss the possible 
applications within the field of tissue engineering. The outline of the procedure is given in 
Table 1.
Table 1 Outline of the procedure to prepare injectable type I collagen micro-scaffolds.
Step Preparation of type I collagen micro-scaffolds
1 Swelling o f purifiedco Hagen fibrils in diluted acetic acid
2 De aeration b y  centrifugation
3 Homogénisation using Potter-Elvehjem with intervening space o f 0 35 mm
4 Freezing at -8CTC
5
Pulverisation using a cutting mill with defined sieve inserts 
(e.g.O.5, 1.0 or 2.0 mm meshes)
6 Freeze drying
7 EDC/NHS crosslinking under stirring conditions
8 Freezing in liquid nitrogen and freeze drying
MATERIALS & METHODS
Fibrillar type I collagen was isolated from 6 months old bovine achilles tendon using a 
series of NaCl, acetic acid, urea and acetone extractions (11). After purification, type I colla­
gen suspensions were prepared in 0.25 M acetic acid (0.8% w/v) and shaken for 16 h at 4°C. 
The suspension was homogenised on ice using a Potter-Elvehjem homogeniser with a inter­
vening space of 0.35 mm (20 strokes). Air bubbles were removed by centrifugation at 525 g 
for 10 min at 4°C. The suspension was poured into 50 ml tubes and frozen at -80°C for 16 h. 
To prepare micro-scaffolds with different sizes, frozen collagen suspensions were pulverised 
under liquid nitrogen conditions using a Pulverisette 19 cutting mill with three different sieve 
inserts (0.5, 1.0 or 2.0 mm meshes) (Fritsch, Idar-Oberstein, Germany). Pulverised material 
was subsequently lyophilised in a Zirbus lyophiliser (Sublimator 500 II, Bad Grund, Germany). 
Freeze-dried collagen was crosslinked by means of N-ethyl-3-(3-dimethylaminopropyl)- 
carbodiimide (EDC, Fluka Chemica, AG Buchs, Switzerland) and N-hydroxysuccinimide (NHS, 
Fluka Chemica, AG Buchs, Switzerland). Briefly, 250 mg collagen was pre-incubated in 100 ml 
50 mM 2-morpholinoethane sulfonic acid (MES) pH 5.0 containing 40% (v/v) ethanol in Mil- 
liQ water for 30 min at 4°C. Then, collagen was crosslinked for 4 h at 21°C under stirring con­
ditions (magnetic stirrer) by adding 100 ml EDC/NHS (final concentrations 33 mM/6 mM, 
respectively) in MES buffer (11). Crosslinking was stopped by adding 200 ml 0.1 M Na2HPO4 
and incubation for 1 h at 21°C under stirring conditions (2 times). The crosslinked collagen
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was washed with 1 M NaCI (2 times 1 h), 2 M NaCI (5 times 30 min) and MilliQ water (6 times 
30 min), using centrifugation (1750 g, 20 min, 21°C) after each step to recover the micro­
scaffolds. Crosslinked collagen micro-scaffolds were frozen in liquid nitrogen and lyophilised.
The collagen micro-scaffolds were evaluated using conventional light microscopy (LM) 
and scanning electron microscopy (SEM). For LM analysis, the micro-scaffolds were 
resuspended in MilliQ water and analysed using a DM IL Leica microscope (Leica Micro­
systems, Wetzler, Germany). For SEM analysis, dried micro-scaffold were mounted on stubs, 
sputtered with an ultrathin layer of gold in a Polaron E5100 Coating System, and studied 
with a JEOL JSM-6310 SEM (JEOL Ltd, Tokyo, Japan) apparatus at an accelerating voltage of 
15 kV.
Injectables were prepared by resuspending 0.5% (w/v) micro-scaffolds in MilliQ water. 
The injectability was tested by injecting 1 ml suspension through 18-21 Gauge sized needles 
(BD Microlance™ 3, BD, Drogheda, Ireland).
RESULTS
Figure 1 shows the morphology of crosslinked collagen micro-scaffolds with three 
different sizes. Only the crosslinked samples resulted in micro-scaffolds with an intact net­
work (Fig. 1A2). Without crosslinking, micro-scaffolds partly fell apart resulting in small 
collagen structures (Fig. 1A1). Both LM and SEM analysis revealed that the collagen micro­
scaffolds were highly porous (Fig. 1B). The structures contained lattice-like lamellae mostly 
orientated parallel or perpendicular to the surface. The mean scaffold size of the 0.5 mm, 1.0 
mm or 2.0 mm sieved materials was 263 ± 78 Mm, 396 ± 115 Mm, and 988 ± 364 Mm (n=50) 
respectively. From all micro-scaffolds, injectables (0.5% w/v) in MilliQ water could be pre­
pared (Fig. 2). The smallest needles through which the scaffolds could be injected were 21, 
19 and 18 Gauge needles (diameter 0.7, 0.9 and 1.0 mm) for 0.5, 1.0 and 2.0 mm micro­
scaffolds, respectively.
DISCUSSION
Crosslinking has frequently been used to stabilise collagen network and/or to prevent 
rapid degradation in vivo (3). Using crosslinking, it is also possible to covalently attached 
heparin (and glycosaminoglycans in general) to the collagen, making it possible to create a 
niche of (heparin-binding) effector molecules (e.g. growth factors) in order to recruit (pro­
genitor) cells from surrounding tissue, blood or bone marrow. Collagen scaffolds loaded with 
growth factors (i.e. FGF-2 and VEGF) have been used to create specific environments, 
initiating processes such as angiogenesis and tissue remodelling (12). Micro-scaffolds com­
bined with angiogenic factors, may be helpful to induce local neovascularisation in ischemic 
tissues (e.g. in skeletal muscle or skin damaged by trauma or infection, or in myocardium 
that has been affected by infarction). The pore size of the collagen micro-scaffolds was com­
parable to those described for large collagen scaffolds (50-100 Mm) (13). Particular the ~100 
Mm pores favour cell attachment on collagen-glycosaminoglycan scaffolds (14). Next to this, 
it is likely that more cells may attach to the micro-scaffolds, since the surface area is larger. 
In this perspective the micro-scaffolds may function as carriers to deliver cells with a desired 
phenotype to the site of the defect to create specific cell niches, for example to deliver cells 
producing insulin in case of diabetes, or local administration of chondrocytes for topical 
cartilage repair in case of cartilage destruction.
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0.5 mm 1.0 mm 2.0 mm
Fig. 1 Morphology of micro-scaffolds. A) Necessity of crosslinking of the micro-scaffolds (0.5 mm); A1 
non-crosslinked and A2 crosslinked micro-scaffolds. B1-3) Light microscopical images of crosslinked 
micro-scaffolds suspended in MilliQ water. B4-9) Scanning electron microscopical images of dried colla­
gen micro-scaffolds. Micro-scaffolds were prepared using a chopping device with different sieves with 
cut off values of 0.5 mm (B1, B4, B7), 1.0 mm (B2, B5, B8) or 2.0 mm (B3, B6, B9). In A1 and A2 bars 
represent 100 ^m. In B1-3 bars represent 250 ^m, in B4-6 1 mm, and in B7-9 100 ^m.
Fig. 2 Macroscopic image of 5 ml syringes filled with differently sized resuspended micro-scaffolds. In­
jectables were prepared by resuspending 0.5% (w/v) crosslinked type I collagen micro-scaffolds after 
chopping and sieving (0.5 mm, 1.0 mm or 2.0 mm fractions) in MilliQ water. Bar represents 1 cm.
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Micro-scaffolds with BMPs may be useful to initiate local osteoinductivity (e.g. in 
fractured bone or for fusion of lumbar spines), thus facilitating bone formation. In addition, 
micro-scaffolds may act as a bulking agent to treat urinary stress incontinence.
In summary, a straightforward technique has been developed to prepare injectable 
collagenous micro-scaffolds, which may be useful for localised tissue regeneration without 
the need for surgery.
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INTRODUCTION
A number of techniques have been explored to prepare hollow structures (capsules) for 
biomedical applications. Liposomes (self-assembled vesicles composed of (phospho)lipids) 
represent the arch type of biological capsules (1) and are used in vivo in cancer therapy and 
systemic fungal infections. They are usually modified, e.g. by PEGylation, to avoid 
recognition as foreign bodies by the immune system (2). Another class of capsules, the poly- 
mersomes, (3) is based on synthetic monomers including men-made peptide/protein units 
such as poly-Lys backbones grafted with methoxypolyethylene glycol (4). The formation of 
both liposomes and polymersomes is largely driven by the amphiphilic nature of the com­
pounds (5). Other methods for capsule formation that do not rely on amphiphilicity exist, 
e.g. vesicle templating, (6, 7) polyelectrolyte layer-by-layer assembly (8) and colloidosome 
fabrication (9, 10). Due to the procedures employed, synthetic rather than biological building 
blocks are used. For biomedical applications it would be advantageous if capsules could be 
prepared from the vast repertoire of (large) natural macromolecules, preferably without the 
need for amphiphilicity. One such example encompasses hollow microcapsules prepared by 
cavitation methods, e.g. spray-drying of aqueous albumin solutions (11). Capsules thus pre­
pared are applied as contrast agents, but due to the high temperatures employed the bio­
logical activity of the proteins is likely diminished. Another example encompasses micro­
capsules prepared by the complex coacervation method (12) and interfacial polymerisation 
(13).
In this study, we present a general strategy to prepare biocapsules at low temperatures 
from a range of (large) biomolecules. The method is physical rather than chemical in nature, 
and amphiphilicity of the biomolecule is not essential. It is a general methodology that 
enables the preparation of a novel class of nano- to microscale capsules ("lyophilisomes") us­
ing a combined freezing, annealing and lyophilisation procedure. Model studies were per­
formed using a solubilised form of elastin, an extracellular matrix protein that can easily be 
obtained in bulk quantities, and that shows autofluorescence which enables straightforward 
detection. The average molecular mass of the elastin preparation was about 1.1 MDa (for 
further characteristics of the elastin preparation, see Experimental). In a typical experiment, 
a solution of 2.0% elastin in 0.25 M acetic acid in water was fast frozen in liquid nitrogen 
(-196°C), incubated at -10 to -20°C for 3 h (annealing step), and lyophilised (for lyophiliser 
settings, see Fig. 1A). Such a freezing-annealing-lyophilisation regime resulted in globular 
structures ranging from 200 nm - 10 Mm as revealed by scanning electron microscopy (SEM) 
(Fig. 1B). Further analysis by transmission electron microscopy using stabilised (vapour- 
crosslinked) preparations (see Experimental) revealed the capsule nature of these spheres 
(Fig. 1C). The walls of the capsules were smooth and the protein was distributed equally over 
the wall. The width of the wall was about 50-500 nm, depending on the size of the capsule. 
Using fluorescence-activated cell sorting, capsules could be separated according to size (Fig. 
1D). Capsules could be prepared from a variety of macromolecules, including serum albumin 
(67 kDa) as an example of a spherical protein, type I collagen (280 kDa) as an example of a 
rod-like protein, and heparin (15 kDa) as an example of a highly negatively charged poly­
saccharide (Fig. 1E). This indicates that amphiphilicity is not required, in contrast to lipo­
somes and polymersomes.
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Fig. 1 Preparation and morphology of capsules. Elastin capsules were obtained by fast freezing of 2.0% 
elastin in 0.25 M acetic acid using liquid nitrogen (-196°C), followed by annealing at -10  to -20°C and 
lyophilisation. A) representative run of the standard lyophiliser program used for the preparation of 
elastin capsules. The sample is in contact with the plate. Please note that the pressure sensor can only 
accurately measure pressures below 1000 Pa. B) scanning electron micrograph (SEM), and C) transmis­
sion electron micrograph (TEM) of elastin capsules. Capsules displayed a smooth and round 
morphology. The left insert indicates the homogenous distribution of elastin throughout the capsule 
wall, the middle insert shows nanocapsules, and the right insert indicates plasticity of capsules as 
suggested when capsules are in contact with each other. D) SEM micrographs of capsules sorted 
according to size (A-D) using fluorescence-activated cell sorting. e, SEM micrographs of capsules pre­
pared from 0.25% collagen (a rod-like protein), 0.25% bovine serum albumin (a globular protein), and 
1.0% heparin (a highly negatively charged polysaccharide).
Fluorescent-labelled probes were applied to study if (macro)molecules could be 
incorporated in, and subsequently released from, the lumen and/or wall of the capsules (see 
Fig. 2A-C for fluorescent labelled dextrans). For the incorporation into the wall only, probes 
were added to the initial solution, prior to freezing. After capsule formation, probes were 
homogeneously incorporated into the wall with the lumen staying empty (Fig. 2A). To load 
the lumen of the capsule, probes were applied to pre-formed, vapour-crosslinked capsules 
(see Experimental), resulting in their presence in the lumen (Fig. 2A). After loading of the
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lumen, the wall -which hardly contained the probe- could be sealed by further shell 
crosslinking. Hence it was possible to differentially incorporate substances into either the 
capsule wall and/or the capsule lumen. Likewise, we could incorporate antibodies in the wall 
and dextrans in the lumen, and (hydrophilic) dextrans in the wall and lipophilic DiOC18 
molecules in the lumen. Incorporated probes could be released from the stabilised elastin 
capsules by digestion with the enzyme elastase (Fig. 2B, SEM and Fig. 2C, time resolved con- 
focal laser scanning microscopy). Without elastase, no detectable release was observed for 
at least two weeks. To further explore if the biological activity of the biomolecules was pre­
served and not to a major extent affected by the used crosslinking methodology, see 
Experimental), enzymes were incorporated in the capsule wall and in the lumen. In one 
example, peroxidase-labeled IgG was incorporated in the wall and alkaline phosphatase­
labelled IgG was positioned in the lumen. Both enzymes remained bioactive as shown by the 
conversion of chromogenic substrates into coloured reaction products (Fig. 2D, light micro­
scopy).
enzyme digestion
Peroxidase in wall Phosphatase in lumen Peroxidase in wall,
phosphatase in lumen
D 5
Fig. 2 Differential incorporation and release of compounds. A) a 10 kDa dextran probe labelled with Al- 
exa Fluor488 (green) was specifically incorporated into the capsule wall followed by 24 h of vapour 
crosslinking, whereas a similar probe labelled with Alexa Fluor594 (red) was directed to the capsule 
lumen followed by 2 h of wet crosslinking (confocal laser scanning microscopy). B) upon degradation by
0.4 U/ml elastase, elastin capsules were perforated, and reassembled into nanospheres (scanning 
electron microscopy). C) treatment with 0.4 U/ml elastase released the (red) probe from the lumen, 
whereas the (green) probe was partially withheld in the wall. Arrows indicate capsules releasing their 
content in time (time resolved confocal laser scanning microscopy). D) peroxidase-labeled IgG was 
incorporated into the capsule wall followed by 24 h of vapour crosslinking, whereas alkaline 
phosphatase-labelled IgG was positioned in the capsule followed by 2 h of wet crosslinking.
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To study the mechanism of capsule formation, we used fluorescence and freeze micro­
scopy (Fig. 3, see also Fig. 4 for cartoon). Fast freezing in liquid N2 induced a micro-phase 
separation between the bulk of the water (ice crystals) and an elastin/acetic acid/water 
compartment, typical for bi/ternary eutectic phase systems (14). The elastin was present in 
thin sheet-like structures (Fig. 3A; elastin detected on base of its autofluorescence). When 
the temperature of the frozen sample was increased to -10/-20°C and kept at that 
temperature for a period of time (annealing, Fig. 1A), macromolecular motion occurred and 
the sheets reassembled into spheres (Fig. 3B; the Supplementary Material shows a movie of 
this rearrangement).
This process is likely driven by globular structures being energetically more favourable 
than thin sheets (less surface interface). For the transition of spheres into capsules we pro­
pose that during lyophilisation a 3-dimensional analogy of the "coffee stain" mechanism 
occurs (Fig. 4A) (15). The coffee-stain mechanism explains the formation of solid, ring-like 
stains from solution droplets by capillary flow introduced by the larger evaporation of the 
solvent at the edge of the droplet compared to its interior. The solute is deposited as a solid 
ring providing that the contact line at the perimeter of the solution with the solid substrate 
is pinned. In our study, the lyophilisation process takes place at -20°C, which is above the 
eutectic point of an acetic acid in water mixture (-27°C) (14). At -20°C, most of the water is 
frozen (ice crystals), but the biomolecule/acetic acid/water compartment ("the melt") is pre­
sent as a viscous fluid. In the proposed 3D analogy, the perimeter of the biomolecule- 
containing "melt" will be pinned, because it will freeze as a consequence of the subtraction 
of heat due to the sublimation of the bulk of ice crystals facing the "melt". Upon 
lyophilisation the biomolecules in the centre of the "melt" will be forced to the outer edge of 
the sphere where lyophilisation takes place. When all material (ice and acetic acid) is lyo- 
philised, biomolecule capsules remain. This technology will most likely be generally 
applicable to both biological and synthetic polymers. Although this mechanism is hypotheti­
cal, some morphological observations are indicative for the 3D coffee stain theory. For ex­
ample, capsules were observed with uneven wall thickness (probably due to unequal 
sublimation), resembling coffee stains with uneven wall thickness due to unequal 
evaporation (Fig. 4A) (16). Also, capsules were observed with a layered appearance of the 
capsule wall, indicative for wall formation by apposition growth, which also occurs in coffee 
stains that evaporate unevenly (data not shown).
The biocapsules may show great biomedical potential, firstly because of their ability to 
encapsulate both hydrophilic and lipophilic compounds, and secondly because the capsules 
can be prepared in large quantities from biological molecules that are biocompatible and 
biodegradable and which remain bioactive. Although not tested, scaling up the capsule pro­
duction may be rather simple since the methodology works equally well when 1 ml volumes 
are applied. Additionally, by developing a 'droplet machine', many droplets can be fast 
frozen in liquid nitrogen and capsules can be prepared at high quantities. With the possibility 
to incorporate different biomolecules into the capsule wall and the capsule lumen, a two­
way system may be prepared (Fig. 4B). This offers the construction of "smart" capsules, for 
instance those containing pre-active biomolecules (pro-drugs) in the lumen, offering a slow- 
release depot for e.g. therapeutics. Since capsules can be easily prepared in large quantities, 
applications in e.g. tissue engineering are also possible.
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Fig. 3 Formation of elastin sheets and spheres by fast freezing and annealing evaluated by micro­
scopical analysis. A) fast freezing. When a 2.0% elastin solution in 0.25 M acetic acid (left panel) was fast 
frozen in liquid nitrogen (right panel), it became organised in the form of sheets (fluorescence micro­
scopy based on elastin's autofluorescence). B) annealing. When the frozen elastin preparation was 
incubated for 20 min at -40 to -18°C (i.e. above the eutectic point of acetic acid in water), spheres be­
came ap-parent. In this specific example, frames were taken starting at -40°C (t=0 min, 1st frame), -29°C 
(t=5 min, 2nd frame), -22°C (t=11 min, 3rd frame) and -18°C (t=20 min, 4th frame).
Coffee stain analogy
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surface cross-section
o o
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DIFFER EN TIA L INCO RPO RATIO N A N D  R ELEASE
• INCORPORATION 
in capsule wall
in capsule lumen _t_ : P O S S IB L E
A P PLICA TIO N S:
- Drug delivery
- Targeting
- Slow releas«
• Vaccination
- Laboratory-in-a-capsule
Fig. 4 Cartoon of proposed capsule formation and application. A) capsule formation. Capsule formation 
comprises a three-step procedure (freezing -  annealing -  lyophilisation). Fast freezing of biomolecules in 
solution (left upper panel) results in phase separation between water (the main solvent) and bio­
molecules which become organised into sheets (right upper panel). Annealing rearranges the sheets into 
spheres and lyophilisation transforms spheres into capsules, most likely due to a 3D analogy of the 
coffee stain mechanism (see text for further information). B) differential incorporation and release. 
Molecules (~) are selectively incorporated in the capsule wall by adding them to the initial solution from 
which the capsules are made of. Molecules (~) are incorporated in the capsule lumen by incubation with 
vapour-crosslinked capsules. The wall can optionally be sealed by crosslinking. Release can be triggered 
e.g. by digestion of the capsule with an appropriate enzyme.
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In conclusion, we here present the preparation of a new class of capsules, dubbed "lyo­
philisomes". The preparation of these nano/microcapsules comprises three phases: micro­
phase separation by fast freezing, structural rearrangement by annealing and the creation of 
a lumen by lyophilisation according to a 3D analogy of the coffee stain principle (Fig. 4A). 
Amphiphilicity does not seem to be required, thus expanding the type of molecules that can 
be used, including large biomolecules as we show here. Elastin was used as a model system, 
but the methodology works equally well with other bio(macro)molecules. The nature of the 
methodology offers flexibility since all three phases observed in capsule preparation can be 
influenced. Using this cheap and simple technology, a large range of new (bioactive) capsules 
may be anticipated.
EXPERIMENTAL
Preparation and characterisation of elastin
Insoluble elastin was isolated from equine ligamentum nuchae and solubilised by oxalic 
acid hydrolysis (17, 18). The solubilised elastin preparation was analysed by gel electropho­
resis (SDS-PAGE, 4% gel, silver staining), and gel filtration chromatography [Sephacryl S-500 
column material and the reference samples ferritin (0.88 MDa), dextran blue (2 MDa), and 
Helix pomatia haemocyanin (9 MDa)]. The average molecular mass of solubilised elastin was 
about 1,100 kDa. 2D gel electrophoresis showed that the solubilised elastin had an isoelec­
tric point of around 6. Amino acid composition of insoluble elastin and solubilised elastin 
was similar for all amino acid residues, including desmosine and isodesmosine (both 0.5 ± 
0.0 per 1000 amino acid residues) (19).
Preparation of capsules
The standard procedure for the preparation of capsules was to drop 20 Ml of a 2.0% (w/v) 
elastin in 0.25 M acetic acid solution in liquid nitrogen, incubate the frozen droplets at -10 to 
-20°C for about 3 h, and then lyophilise the sample in a Zirbus lyophiliser (Bad Grund, Ger­
many) using the program plotted in Fig. 1a in the main text. Larger volumes (e.g. 1 ml) can 
be applied as well. Vapour crosslinking of elastin capsules was performed in vapour of 25% 
glutaraldehyde: 38% formaldehyde 1:1 for 24 h, optionally followed by wet crosslinking in 
0.5% glutaraldehyde in phosphate buffer pH 7.4 for 2 h. Concentrations for type I collagen 
(Symatese Biomatériaux, Chaponost, France) and bovine serum albumin (Sigma, St. Louis, 
MO, USA) were 0.25% (w/v) and for heparin (Sigma) was 1.0% (w/v).
Incorporation of fluorescent probes into elastin capsules
Fluorescent probes were incorporated in the capsule wall by the addition of 50 Mg probe 
per ml 2.0% (w/v) elastin solution prior to freezing and lyophilisation. Fluorescent probes in­
cluded Alexa Fluor594-labeled goat anti-mouse antibodies (150,000 Da) and Alexa Fluor488 
or 594-labeled dextrans (10,000 Da). Capsule shells were crosslinked for 24 h by vapour 
crosslinking. Incorporation of fluorescent probes in the capsule lumen was performed by a 
96 h incubation of vapour-crosslinked capsules in a solution of 50 Mg probe in either 1 ml 
MilliQ water (for dextrans) or 1 ml ethanol (for DiOC18; see below), followed by wet 
crosslinking, and three washings with MilliQ water or 100% ethanol to remove non-included 
probe. Probes included Alexa Fluor488 or 594-labeled dextran (10,000 Da) and 3,3'- 
dioctadecyloxacarbocyanine perchlorate DiOC18 (882 Da), all from Molecular Probes Europe 
(Leiden, The Netherlands).
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Incorporation of enzymes into elastin capsules
Peroxidase-labeled IgG (Sigma) was incorporated in the capsule wall by the addition of 
100 Mg enzyme per ml 2.0% (w/v) elastin solution prior to freezing and lyophilisation. 
Capsule shells were crosslinked for 24 h by vapour crosslinking. Alkaline phosphatase­
labeled IgG (Dako, Glostrup, Denmark) was incorporated in the capsule lumen (100 Mg 
enzyme per ml 50 mM Tris-HCl for 72 h at 4°C) followed by a 2 h wet crosslinking and 
washed three times with Tris-HCl. Enzyme activities were studied after reaction with Fast 
Red TR Salt for alkaline phosphatase followed by three washing steps with Tris-HCl, and a 
reaction with 3,3-diaminobenzidine tetrahydrochloride (DAB) for peroxidase followed by 
three washings with Tris-HCl (20).
Degradation studies using elastase
Enzymatic degradation of capsules containing fluorescent probes (Alexa Fluor488-labeled 
dextran in the capsule wall and Alexa Fluor594-labeled dextran in the capsule lumen) was 
assessed after incubation with elastase (Sigma) in 100 mM Tris-HCl pH 8.0 and analysed with 
time resolved confocal laser scanning microscopy (CLSM) and scanning electron microscopy 
(SEM). Specimens were treated with 0.4 U/ml elastase and analysed up to 30 min at 22°C.
Microscopical techniques
Scanning electron microscopy (SEM): Lyophilised samples were sputtered with gold and 
studied with a JEOL JSM-6310 SEM apparatus with an accelerating voltage of 15 kV. Wet 
samples first were critical point dried using liquid CO2. Transmission electron microscopy 
(TEM): Vapour crosslinked samples (stabilised samples) were post-fixed with 0.5% 
glutaraldehyde in 10 mM PB (pH 7.4) for at least 24 h followed by 1% (w/v) osmium 
tetroxide in 0.1 M PB for 1 h. After a rinsing period of 3 h with 0.1 M phosphate buffer, sam­
ples were de-hydrated in an ascending series of ethanol in water solutions, embedded in ep­
oxy resin (Epon 812). Sections (60 nm) were picked up on formvar-coated grids, post stained 
with lead citrate and uranyl acetate, and examined in a JEOL 1010 electron microscope. 
Fluorescence-activated cell sorting (FACS): The average size of the stabilised capsules was 
analysed by flow cytometry (Epics Elite flow cytometer, Coulter, Luton, UK). Capsules were 
gated according to their forward and side scattering patterns. Fractions were collected on 
poly-D-lysine coated coverslips and left to attach for 60 min. Coverslips were critical point 
dried, sputtered with gold, and studied by SEM. Fluorescence microscopy: Elastin 
preparations (2.0% (w/v) in 0.25 M acetic acid) were placed on a glass slide and studied be­
fore and after freezing in liquid nitrogen, using a fluorescence microscope with an I3 filter 
(Leica, DM 6000 B, Leica Microsystems, Wetzler, Germany). Freeze microscopy: A droplet of 
2.0% (w/v) elastin in 0.25 M acetic acid was put on a glass slide, frozen in liquid nitrogen and 
analysed in a -70°C precooled custom-built freeze microscope with temperature registration 
(RIVM National Institute for Public Health and the Environment, Bilthoven, The Netherlands). 
The temperature of the frozen sample was increased until a temperature of -18°C was 
reached. Confocal microscopy: Elastin capsules with incorporated fluorescent probes were 
deposited on poly-D-lysine coated coverslips. Confocal images were made at 488 nm and 
594 nm with a BioRad MRC1024 confocal laser scanning microscope, equipped with an ar­
gon/krypton laser, using a 60x 1.4 NA oil objective and LaserSharp2000 acquisition software. 
Light microscopy: Capsules with incorporated enzymes were placed on a glass slide, stained 
as described above and studied using a Leica DM 6000 B microscope.
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SUPPLEMENTARY MATERIAL
Movie showing annealing of frozen samples
The file Daamen et al movie.avi shows the change in morphology of 2.0% (w/v) elastin in
0.25.M acetic acid frozen in liquid nitrogen and incubated for 27 min at -70 to -18°C as
analysed by freeze microscopy. In this process, spheres formed out of the thin sheets, sug­
gesting that annealing is necessary to obtain globular structures.
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SUMMARY
The general aim of tissue engineering and regenerative medicine is to restore or replace 
damaged tissues and organs by using biomaterials with or without cells. Biomaterials must 
have the capacity to become structurally integrated with the surrounding tissue, and initiate 
or restore local processes. Within regenerative medicine, different strategies with respect to 
biomaterials are known, e.g. the use of scaffolds, injectables, coatings and delivery devices.
The first part of this thesis describes the tools, preparation and evaluation of composite 
collagen-based biomaterials that create a specific microenvironment for tissue regeneration. 
The second part of this thesis describes the tools and potential clinical applications of 
injectable collagen to induce local hemostasis. The third part of this thesis describes the 
preparation of novel delivery vehicles for drugs/cells, based on natural matrix molecules.
PART 1: TOOLS, PREPARATION AND EVALUATION OF COLLAGEN-BASED BIOMATERIALS 
FOR TISSUE ENGINEERING
In Chapter 1 an overview is given of the fundamental aspects of the preparation of 
collagen-based scaffolds for soft tissue engineering, in particular scaffolds composed of type
I collagen, elastin, glycosaminoglycans and growth factors. The aim of tailor-made scaffolds 
for tissue engineering is to resemble the extracellular matrix composition of a specific tissue. 
Collagen has been used as a biological constituent for biomaterials, due to its bio­
compatibility and good mechanical and biological properties. Collagen-glycosaminoglycan 
scaffolds offer the opportunity to regulate cellular activities, and the binding and sustained 
release of growth factors (i.e. heparin-binding growth factors; VEGF, FGF-2 or EGF), resulting 
in a bio-active scaffold. The addition of growth factors to acellular scaffolds may increase 
angiogenesis. Therefore, large-scale production and purification of growth factors is 
desirable for tissue engineering. In Chapter 2, the cloning of rat recombinant VEGF-164, its 
expression in a Pichia pastoris expression system, and the production of large quantities of 
the growth factor using fermentation is described. The produced rat recombinant VEGF was 
shown to be biologically active. In Chapter 3, the rat VEGF was used to construct scaffolds 
with different combinations of type I collagen, heparin, rrFGF-2 and rrVEGF-164, and the tis­
sue response after subcutaneous implantation in rats was evaluated. The combination of 
VEGF and FGF-2 resulted both in a larger area of blood vessels and a more developed vascu­
lature in the a-cellular scaffolds.
PART 2: TOOLS AND POTENTIAL CLINICAL APPLICATIONS OF INJECTABLE COLLAGEN TO 
INDUCE LOCAL HEMOSTASIS
Collagen is biocompatible and biodegradable which allows remodelling in the host after 
implantation. These characteristics, in combination with its hemostatic activity, make 
collagen a good candidate for femoral artery pseudoaneurysm (PSA) treatment. Chapter 4 
describes the development of a porcine femoral PSA model using a one-step surgical pro­
cedure. The model involved the preparation of an arteriovenous shunt between the femoral 
artery and femoral vein, segmenting ~2 cm of the vein using proximal and distal ligatures. 
Chapter 5 describes the preparation and characterisation of highly purified injectable fibrillar 
type I collagen and its evaluation in the PSA model. The outcome of this study indicated that 
sterilised injectable collagen can be prepared without major loss of its structural characteris­
tics and platelet activity, and that in vivo, the injectable collagen formed a dense network
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and triggered (partial) local hemostasis. Although optimisation is needed, injectable collagen 
fibrils may be useful for femoral PSA treatment.
PART 3: PREPARATION OF NOVEL DELIVERY VEHICLES, BASED ON NATURAL MATRIX 
MOLECULES: MICRO-CAPSULES AND MICRO-SCAFFOLDS
With respect to in vivo applications, it would be a major advantage if drug delivery 
vehicles or micro-carriers could be prepared from tissue derived molecules. In Chapter 6 and 
Chapter 7 the preparation of micro-capsules and micro-scaffolds from natural molecules is 
described. Both techniques rely on a combination of freezing/lyophilisation techniques. In 
the initial freezing step, the protein-water-acetic acid solution/suspension phase separates 
from the ice (water only). Differently sized micro-scaffolds (Chapter 6) can be prepared by 
pulverising frozen collagen suspensions under liquid nitrogen conditions using a cutting mill 
with defined sieve inserts and a subsequent lyophilisation step, followed by EDC/NHS 
crosslinking. Micro-scaffolds displayed an open porous network with lamellae formed after 
the freezing and freeze drying step. In case of microcapsules (Chapter 7), globules are 
formed during the freezing and annealing step of the process. In the subsequent lyo­
philisation step, ice sublimates resulting in dry protein with a defined capsule-like structure. 
The preparation of microcapsules was critically depended on annealing during freezing and 
protein concentration. The microcapsules show potential for in vivo targeting and drug 
delivery, whereas injectable micro-scaffolds can function as carrier for cells and effector 
molecules such as glycosaminoglycans and growth factors, thus allowing tissue regeneration 
without the need of surgery.
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The use of specific growth factors in combination with collagen-based scaffolds is 
described in this thesis. Growth factors were shown to be key factors in acellular constructs. 
We found enhanced angiogenesis in collagen-based scaffolds combined with glyco- 
saminoglycans, VEGF and FGF-2. It is highly plausible that the use of multiple growth factors 
may result in even more tissue specific regeneration. Since many tissues have a specific or­
ganisation (e.g. skin, bladder, urethra), special attention must be given to localisation, dose 
and release of the growth factors. In this respect, a possible application for lyophilisomes is 
to act as micro-containers for growth factors. This study showed that it is possible to incor­
porate different biomolecules into the capsule wall and/or lumen of the capsule. This two­
way system offers the construction of "smart" capsules, for instance those containing bio­
molecules (growth factors) in the lumen and/or extracellular matrix molecules in the wall. 
This may generate a slow-release depot of signalling molecules in collagen-based scaffolds. 
In addition, injectable micro-scaffolds with both glycosaminoglycans and growth factors 
generate the possibility to enhance local tissue regeneration without surgery. The composi­
tion and structure of the injectable micro-scaffolds make them potential carriers to create a 
niche of growth factors and/or cells in damaged tissue, e.g. to induce local neo- 
vascularisation in ischemic tissue.
Another strategy which is described in this thesis is the use of collagen for local hemo­
stasis to treat pseudoaneurysms (PSA). Although further research is needed, the outcome of 
the in vivo study indicated that injectable collagen may be an effective therapeutic alter­
native for the current PSA treatment. New collagen-based injectables may be necessary to 
improve its efficacy. Particularly for femoral PSA treatment, it might be attractive to com­
bine collagen fibrils with thrombin to not only initiate the primary hemostasis but also in­
duce the secondary (clotting factor mediated) hemostasis. In addition, the combination of 
contrast agents may assist in the proper follow-up after treatment. Depending on the clinical 
relevance, combinations of collagen-based material with other natural biomaterials may 
create new clinical applications, and have high potential in the field of tissue engineering and 
reconstructive medicine.
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SAMENVATTING
Het algemene doel van weefseltechnologie en regeneratieve geneeskunde is om middels 
materialen, met of zonder cellen, beschadigde weefsels en organen te herstellen of te ver­
vangen. Deze biomaterialen moeten de eigenschap hebben om in het omliggende weefsel te 
kunnen integreren en derhalve lokale processen te stimuleren of te herstellen. Met be­
trekking tot biomaterialen zijn er binnen de regeneratieve geneeskunde verschillende 
strategieën bekend, bijvoorbeeld het gebruik van dragermaterialen (matrices), injecteerbare 
materialen, coatings en afgiftesystemen.
Het eerste gedeelte van dit proefschrift beschrijft de benodigdheden, de bereiding en de 
evaluatie van op collageen gebaseerde biomaterialen, die de mogelijkheid bieden een speci­
fieke micro-omgeving te creëren en zo voor weefselherstel te zorgen. Het tweede deel van 
dit proefschrift beschrijft de benodigdheden en de potentiële klinische toepassingen van 
injecteerbaar collageen voor lokale hemostase. Het derde onderdeel van dit proefschrift be­
schrijft het maken van nieuwe materialen die gebaseerd zijn op natuurlijke matrixmoleculen 
en die mogelijkheden bieden voor afgifte van medicijnen en/of cellen.
DEEL 1: BENODIGDHEDEN, BEREIDING EN EVALUATIE VAN OP COLLAGEEN GEBASEERDE 
BIOMATERIALEN VOOR WEEFSELTECHNOLOGIE
In hoofdstuk 1 wordt een overzicht gegeven van de fundamentele aspecten van de be­
reiding van op collageen gebaseerde matrices voor weefseltechnologie, bestaande uit 
collageen type I, elastine, glycosaminoglycanen en groeifactoren. Met deze op maat ge­
maakte dragermaterialen wordt de extracellulaire matrix van een bepaald type weefsel na­
gebootst. Collageen wordt vaak gebruikt als hoofdbestanddeel van biomaterialen vanwege 
de biocompatibiliteit en de goede mechanische en biologische eigenschappen. Drager- 
materialen bestaande uit collageen en glycosaminoglycanen bieden de mogelijkheid om het 
celgedrag en de afgifte van groeifactoren (heparine bindende groeifactoren zoals VEGF, FGF-
2 of EGF) te reguleren, waardoor deze ook wel bioactieve dragermaterialen worden ge­
noemd. De toevoeging van groeifactoren aan acellulaire dragermaterialen kan bijvoorbeeld 
de bloedvat-ingroei stimuleren. Daarom is een grootschalige productie en zuivering van der­
gelijke groeifactoren binnen de weefseltechnologie zeer gewenst. In hoofdstuk 2 wordt het 
kloneren van recombinant rat VEGF-164, de expressie in het Pichia pastoris expressie- 
systeem en het grootschalig produceren van deze groeifactor middels fermentatie be­
schreven. Het geproduceerde recombinant rat VEGF blijkt biologisch actief te zijn. In hoofd­
stuk 3 wordt de bereiding van dragermaterialen met verschillende combinaties van type I 
collageen, heparine, FGF-2 en VEGF-164 beschreven en worden deze materialen na sub- 
cutane implantatie in ratten geëvalueerd. De combinatie van VEGF en FGF-2 stimuleert de 
ontwikkeling van grotere en beter ontwikkelde bloedvaten in acellulaire dragermaterialen.
DEEL 2: BENODIGDHEDEN EN MOGELIJKE KLINISCHE TOEPASSINGEN VAN INJECTEERDARE 
COLLAGEEN PREPARATEN VOOR LOKALE HEMOSTASE
Collageen is biocompatibel en biologisch afbreekbaar, waardoor herstel in het lichaam na 
implantatie mogelijk wordt gemaakt. Deze eigenschappen, in combinatie met de hemo- 
statische activiteit, maakt collageen een goede kandidaat voor de behandeling van femorale 
pseudoaneurysma (PSA). Hoofdstuk 4 beschrijft de ontwikkeling van een femoraal PSA
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varkensmodel, gebruikmakend van één chirurgische ingreep. Een arterioveneuze shunt 
wordt aangelegd tussen de arteria femoralis en venafemoralis, in combinatie met het seg­
menteren van ~2 cm vene middels proximale en distale knopen. Hoofdstuk 5 beschrijft de 
bereiding en karakterisatie van hoogwaardig gezuiverd injecteerbaar fibrillair collageen type 
I en de toepasbaarheid ervan in het PSA model. Uit deze studie blijkt dat injecteerbaar 
collageen gesteriliseerd kan worden zonder al te veel verlies van de structurele eigenschap­
pen en bloedplaatjesactiviteit. Na toediening in vivo, vormt het injecteerbare collageen een 
compact netwerk en induceert (gedeeltelijk) de lokale hemostase. Hoewel optimalisatie 
nodig is, zou injecteerbaar collageen een alternatief kunnen bieden voor de behandeling van 
femorale PSA.
DEEL 3: BEREIDING VAN NIEUWE AFGIFTESYSTEMEN OP BASIS VAN NATUURLIJKE MATRIX 
MOLECULEN: MICROCAPSULES EN MICRODRAGERS.
Met betrekking tot in vivo toepassingen zou het een groot voordeel zijn als afgifte- 
systemen en microdragers uit natuurlijke moleculen gemaakt kunnen worden. In hoofdstuk 
6 en hoofdstuk 7 wordt de bereiding van microcapsules en microdragers uit natuurlijke mo­
leculen beschreven. Beide technieken zijn gebaseerd op een combinatie van vries- en vries- 
droogtechnieken. De initiële bevriezingsstap zorgt voor een fasescheiding resulterend in een 
eiwit-azijnzuur-water mengsel en ijs (water alleen). Microdragers van verschillende grootte 
(hoofdstuk 6) kunnen worden bereid door de collageensuspensie in vloeibare stikstof in te 
vriezen, te verpulveren in een machine met verschillende zeefgroottes, te vriesdrogen en 
uiteindelijk te crosslinken middels EDC/NHS. De microdragers vormen dan een open en 
poreus netwerk met lamellen. In geval van microcapsules (hoofdstuk 7), worden er tijdens 
het invriezen en incuberen kleine bolletjes gevormd. In de daaropvolgende vriesdroogstap 
sublimeert het ijs hetgeen resulteert in droog eiwit met een gedefinieerde bolstructuur. De 
bereiding van microcapsules is afhankelijk van de eiwitconcentratie en de incubatietijd 
tijdens het invriezen. De microcapsules zouden mogelijk toegepast kunnen worden voor 
gereguleerde medicijnafgifte in vivo. De injecteerbare microdragers kunnen mogelijk worden 
gebruikt voor het lokaal toedienen van cellen en effectormoleculen, zoals glycosamino- 
glycanen en groeifactoren, waardoor weefselregeneratie zonder een invasieve ingreep 
mogelijk wordt gemaakt.
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In dit proefschrift wordt het gebruik van specifieke groeifactoren in combinatie met 
collagene dragermaterialen voor toepassing in regeneratieve geneeskunde beschreven. Uit 
dit onderzoek bleek dat groeifactoren belangrijke factoren zijn voor acellulaire constructen. 
In deze studie observeerden we dat de bloedvatvorming wordt bevorderd als collageen dra­
germaterialen worden gecombineerd met glycosaminoglycanen, VEGF en FGF-2. Het is aan­
nemelijk dat ook bij gebruik van andere weefselgerelateerde groeifactoren er een meer 
weefselspecifieke regeneratie wordt geïnduceerd. Aangezien veel weefsels een specifieke 
organisatie hebben (bijv. huid, blaas, urethra), moet er meer aandacht worden besteed aan 
de locatie, dosering en afgifte van deze groeifactoren. Een mogelijkheid is om lyophilisomes 
als microcontainers voor groeifactoren te gebruiken. Dit onderzoek heeft aangetoond dat 
het mogelijk is om verschillende biomoleculen in de wand en/of lumen van de capsules te 
lokaliseren. Deze twee-weg strategie biedt de mogelijkheid om "slimme" capsules te maken, 
bijvoorbeeld capsules met biomoleculen (groeifactoren) in het lumen en/of extracellulaire 
matrix moleculen in de wand. In combinatie met op collageen gebaseerde dragers zouden 
deze capsules voor een langzame en gecontroleerde afgifte van dergelijke signaalmoleculen 
kunnen zorgen. Daarnaast hebben injecteerbare microdragers in combinatie met glyco­
saminoglycanen en groeifactoren de mogelijkheid om lokaal de weefselregeneratie te stimu­
leren zonder gebruik te maken van een chirurgische ingreep. Door de samenstelling en struc­
tuur van de injecteerbare micro-dragers zijn het in potentie goede materialen voor het lo­
kaal aanbrengen van groeifactoren en/of cellen in beschadigd weefsel, bijvoorbeeld voor het 
stimuleren van neovascularisatie in ischemisch weefsel.
Een andere strategie die in dit proefschrift is beschreven, is het gebruik van collageen als 
hemostatisch middel voor de behandeling van pseudoaneurysma (PSA). Het in vivo onder­
zoek heeft aangetoond dat het injecteerbare collageen een mogelijk therapeutisch 
alternatief is voor de behandeling van PSA, hoewel verder onderzoek noodzakelijk is. Nieuwe 
injecteerbare collageenpreparaten zijn nodig om de effectiviteit te verbeteren. Vooral voor 
femorale PSA behandeling kan het aantrekkelijk zijn om collageenfibrillen te combineren 
met thrombine, om zo naast de primaire bloedstolling ook de secundaire stolling (stollings- 
factor gemedieerde stolling) te stimuleren. Bovendien zou een combinatie met een contrast­
middel ervoor kunnen zorgen dat de preparaten beter te volgen zijn in het lichaam, wat zo­
wel het onderzoek als de behandeling kan vereenvoudigen.
In zijn algemeenheid kan gesteld worden dat collagene materialen in combinatie met 
andere natuurlijke biomaterialen veel potentie hebben voor weefseltechnologie en recon­
structieve geneeskunde en gebruikt kunnen worden voor nieuwe klinische toepassingen.
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Chapter 1. Fig 4 Immunostaining of scaffolds containing variable amounts of collagen and elastin with 
covalently attached chondroitin sulfate using immunostaining for type I collagen (red) and CS (green), 
whereas elastin was analysed by UV optics (blue). Bar is 50 ^m. COL=collagen, EL=elastin, 
CS=chondroitin sulphate. Figure modified with permission from Daamen etal. (5).
Chapter 7. Fig. 2 Differential incorporation and release of compounds. A) a 10 kDa dextran probe la­
belled with Alexa Fluor488 (green) was specifically incorporated into the capsule wall followed by 24 h 
of vapour crosslinking, whereas a similar probe labelled with Alexa Fluor594 (red) was directed to the 
capsule lumen followed by 2 h of wet crosslinking (confocal laser scanning microscopy). B) upon degra­
dation by 0.4 U/ml elastase, elastin capsules were perforated, and reassembled into nanospheres (scan­
ning electron microscopy). C) treatment with 0.4 U/ml elastase released the (red) probe from the 
lumen, whereas the (green) probe was partially withheld in the wall. Arrows indicate capsules releasing 
their content in time (time resolved confocal laser scanning microscopy). D) peroxidase-labeled IgG was 
incorporated into the capsule wall followed by 24 h of vapour crosslinking, whereas alkaline phos­
phatase-labelled IgG was positioned in the capsule followed by 2 h of wet crosslinking.
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